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The ubiquitin proteasome system (UPS) is required for normal cell proliferation, vertebrate
development, and cancer cell transformation. The UPS consists of multiple proteins that
work in concert to target a protein for degradation via the 26S proteasome. Chains of an
8.5-kDa protein called ubiquitin are attached to substrates, thus allowing recognition by the
26S proteasome. Enzymes called ubiquitin ligases or E3s mediate speciﬁc attachment to
substrates. Although there are over 600 different ubiquitin ligases, the Skp1–Cullin–F-box
(SCF) complexes and the anaphase promoting complex/cyclosome (APC/C) are the most
studied. SCF involvement in cancer has been known for some time while APC/C’s can-
cer role has recently emerged. In this review we will discuss the importance of APC/C to
normal cell proliferation and development, underscoring its possible contribution to trans-
formation. We will also examine the hypothesis that modulating a speciﬁc interaction of
the APC/C may be therapeutically attractive in speciﬁc cancer subtypes. Finally, given that
the APC/C pathway is relatively new as a cancer target, therapeutic interventions affecting
APC/C activity may be beneﬁcial in cancers that are resistant to classical chemotherapy.
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INTRODUCTION
Any discussion of the anaphase promoting complex/cyclosome
(APC/C) pathway as a possible therapeutic target has to start
with the question of what makes APC/C unique among the many
ubiquitin ligases present in human cells. On one level APC/C is
mechanistically similar to the Skp1–Cullin–F-box (SCF) ubiquitin
ligases where there are core subunits and an adaptor protein that
directly binds to a substrate. In SCFs, the four subunits are Skp1
(scaffold protein), Cul1 (scaffold protein), RING-ﬁnger compo-
nent (Rbx1), and the variable adaptor protein or F-box protein
that recognizes substrates (Zheng et al., 2002). In APC/C there are
13 subunits as well as variable adaptor proteins termed Cdc20 (or
Fizzy; Fzy), Cdh1 (or Fizzy-related; Fzr), Cortex, Ama1, or Mfr1
Abbreviations: APC/C, anaphase promoting complex/cyclosome; bHLH, basic
helix–loop–helix; BMP, bone morphogenetic protein; Cdc20, cell division cycle
protein 20 or Fizzy, Fzy; Cdh1, Cdc20 homolog 1, or Fizzy-related, Fzr; Cdk,
cyclin-dependent kinase; CK1, casein kinase 1; D-boxes, destruction boxes; E1,
ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; E3, ubiquitin lig-
ases; Emi1, early mitotic inhibitor-1/Rca1; HAT, histone acetyltransferase; HDAC,
histone deacetylase; HEC1, high expression in cancer 1; Id1, inhibitor of DNA
binding 1; Id2, inhibitor of DNA binding 2, also known as inhibitor of differ-
entiation 2; JNK, c-Jun NH2-terminal kinase; MAK, male germ cell-associated
kinase; MCM, minichromosome maintenance; MEF, mouse embryonic ﬁbrob-
last; MR, methionine–arginine; NAALADase, N -acetylated alpha-linked acidic
peptidase; Nek2, NIMA-related kinase 2; NGF, nerve growth factor; OSCC, oral
squamous cell carcinomas; PC, proteasome/cyclosome; PCNA, proliferating cell
nuclear antigen; PIP3, phosphoinositide-3,4,5-triphosphate; Plk1, polo-like kinase
1; PMSA, prostate speciﬁc membrane antigen; pRb, retinoblastoma protein; preRC,
pre-replicative complex; Rbx1, RING-ﬁnger component; SCF, Skp1–Cullin–F-box;
TAME, tosyl-l-arginine methyl ester; TGF-β, transforming growth factor beta; TPR,
tetratricopeptide repeat; UPS, ubiquitin proteasome system.
(Acquaviva and Pines, 2006; Hutchins et al., 2010; Kops et al.,
2010). However, beyond these similarities regarding adaptors and
subunits present in APC/C and SCF ligases, large differences in
size and structure exist between these two types of ligases. By
contrast to SCF ubiquitin ligases, there is only limited knowl-
edge regarding APC/C structure mainly because the enormous
size and complexity of the holoenzyme present signiﬁcant chal-
lenges for structure determination at the atomic level. The ﬁrst
structural insights into the APC/C was obtained by cryo-EM of
complexes puriﬁed from human cells, Xenopus laevis egg extracts,
and budding yeast (Gieffers et al., 2001; Dube et al., 2005; Pass-
more et al., 2005). 3D modeling showed that in all cases theAPC/C
is an asymmetric triangular complex (200 by 230Å in size), com-
posed of an outer wall and an internal cavity. Cdh1 and the Cullin
domain of the Apc2 subunit are located on the outside of the
complex, making it plausible that ubiquitination reactions occur
on the outside and not inside the cavity. An emerging view of
the APC/C is that of a four-part enzyme composed of a struc-
tural arm or scaffolding unit made of Apc1, Apc4, and Apc5, a
catalytic arm consisting of Apc2, Apc11, and Doc1 (or Apc10),
a tetratricopeptide repeat (TPR) arm made of Cdc23, Cdc16,
and Cdc27, which mediates binding to activators and coactiva-
tors (Cdc20, Cdh1, Cortex). Other subunits such as Cdc26, Apc9,
and Swm1 stabilize the TPR arm (Schwickart et al., 2004; Thorn-
ton and Toczyski, 2006). The TPR subunits have 12–15 copies of
the 34-amino acid long TPR. They facilitate interactions between
subunits and the assembly of multisubunit complexes (Zachariae
and Nasmyth, 1999). A pseudo-atomic model of the yeast APC/C
obtained by reconstitution studies of the holoenzyme and its sub-
complexes has revealed that the TPR arm along with the structural
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arm coordinate the juxtaposition of the catalytic arm and the TPR
phosphorylation sites relative to the coactivators, substrates, and
regulators (Schreiber et al., 2011).
A previously unidentiﬁed APC/C subunit, Apc16, was reported
recently (Hutchins et al., 2010; Kops et al., 2010). It is a small pro-
tein of 11.7 kDa in size encoded by Chromosome 10 open reading
frame 104 (C10orf104) in humans. Apc16 may facilitate Cdc27
hyperphosphorylation, although it is not essential for assembly
of the holocomplex (Kops et al., 2010). Therefore, the APC/C is
composed of multiple subunits, some of which are newly dis-
covered. However, the minimum ubiquitin ligase module of the
APC/C that can catalyze ubiquitination is comprised of just two
subunits – the Apc2 Cullin subunit and the Apc11 RING subunit
(Gmachl et al., 2000; Leverson et al., 2000; Tang et al., 2001),which
are analogous to the Cullin and Rbx1 subunits of the SCF com-
plex (Barford, 2011). Thus, while we still do not have a complete
understanding of APC/C structure, we are beginning to under-
stand the general architecture of the complex, and possibly achieve
an atomic level resolutionofAPC/C subcomplexes. These subcom-
plexes may provide multiple binding sites for small molecules that
would perhaps make APC/C unique among ubiquitin ligases as a
therapeutic target.
APC/C ACTIVITY
Another attractive aspect of the APC/C as a drug target is that it
binds a unique set of enzymes required for transferring ubiqui-
tin to substrates. The process of ubiquitination begins with the
ubiquitin-activating enzyme E1 binding to and activating ubiqui-
tin in an ATP-dependent manner. This activated ubiquitin is then
transferred to a ubiquitin-conjugating enzyme or E2. The ubiq-
uitin ligases or E3 enzymes then associate with E2s to catalyze
the ubiquitin transfer to the ε-amino group of lysine residues
on substrate proteins (Ye and Rape, 2009). Multiple ubiquitin
molecules can be linked together in different ways to form polyu-
biquitin chains that satisfy different objectives. In yeast, chains
linked via Lysine 48 of ubiquitin (K48 chains) are a “proteolytic
signal” whereas those linked via Lysine 63 (K63 chains) function
as molecular scaffolds. In higher eukaryotes, the APC/C is known
to build atypical K11-linked polyubiquitin chains on its substrates
in association with its unique E2 partner, Ube2C (or UbcH10;
Wickliffe et al., 2011b). Ube2C only initiates chain formation,
however. Chain elongation is carried out by a K11-speciﬁc E2
called Ube2S (or E2–EPF) that works with both APC/CCdc20 and
APC/CCdh1 (Garnett et al., 2009; Wu et al., 2010; Wickliffe et al.,
2011a). The importance of this dual regulation of APC/C activity
via Ubch10 and Ube2S is underscored by the ﬁnding that remov-
ingK11-speciﬁc E2s causes defects in spindle assembly andmitotic
progression (Williamson et al., 2009).
One of the most attractive means of attenuatingAPC/C activity
pharmacologically is by modulating the adaptor protein–substrate
binding reaction. Early studies in yeast identiﬁed the Cdc20 and
Cdh1 substrate binding adaptor proteins as required for APC/C
activity (Visintin et al., 1997). Subsequent studies in multiple
experimental systemsdemonstrated the biochemical requirements
for these adaptors to bind their substrates (Fang et al., 1998).
Although exceptions exist, Cdc20 and Cdh1 bind substrates con-
taining the sequence elements RXXLXXXXN/D/E or destruction
boxes (D-boxes), while Cdh1 can also bind substrates contain-
ing KEN sequences (Glotzer et al., 1991; Pﬂeger and Kirschner,
2000). Substrate binding initiates ubiquitination mediated by
APC/CCdc20 or APC/CCdh1. However, APC/CCdc20 or APC/CCdh1
mediated substrate binding is controlled during the cell cycle using
an overlapping series of regulatory mechanisms. Inhibitory com-
plexes control APC/C activity during the cell cycle, thus limiting
its activity to deﬁned temporal windows (for reviews see Man-
chado et al., 2010; Qiao et al., 2010; Pines, 2011). One of the most
important examples of this is the exquisite control of APC/CCdc20
activity during mitosis. In early mitosis, APC/CCdc20 activity is
curtailed by the spindle assembly checkpoint (SAC), which mon-
itors the attachment of kinetochores to the mitotic spindle. An
inhibitory complex containing Mad2, Bub3, and BubR1 proteins
sequesters Cdc20 and renders it unable to bind substrates (Kim
and Yu, 2011). After the checkpoint is switched off, this com-
plex is released from APC/CCdc20, which initiates the metaphase
to anaphase transition by mediating degradation of key proteins
such as securin, shugoshin, and cyclin B1 (Kim and Yu, 2011).
Securin and cyclinB1degradation activates separase,which cleaves
the cohesin complex that holds sister chromatids together while
shugoshin destruction relieves sister chromatid cohesion at the
centromere (Wang and Dai, 2005). These reactions are essential
for the metaphase to anaphase transition, which is inhibited when
APC/C activity is abrogated pharmacologically or by siRNA deple-
tion or genetic disruption of Cdc20 (Huang et al., 2009;Manchado
et al., 2010; Zeng et al., 2010). Cells lacking APC/CCdc20 eventu-
ally undergo mitotic catastrophe and die in a manner reminiscent
of microtubule inhibition (Zeng et al., 2010). However, APC/C
inhibitory molecules may have the added advantage that they
will not have the usual off-target effects of microtubule inhibi-
tion well-known during chemotherapy treatment (Huang et al.,
2009; Manchado et al., 2010).
APC/CCdh1 CONTROLS SEVERAL CELL CYCLE TRANSITIONS
Small molecules that inhibit substrate ubiquitination via
APC/CCdc20 also reduce APC/CCdh1 activity (Zeng et al., 2010).
Since the APC/CCdh1 window of activity during the cell cycle
is larger than that of APC/CCdc20, it may be easier to modulate
APC/CCdh1 speciﬁc pathways necessary for growth of a partic-
ular cancer cell. APC/CCdh1 controls mitotic exit and maintains
the G1-phase in cycling cells (Figure 1). Outside the cell cycle,
APC/CCdh1 is required for quiescence, cell cycle exit, and differ-
entiation (Figure 1). These multiple roles suggest the presence of
distinct upstream regulatory and signaling pathways controlling
APC/CCdh1 within temporal or developmental windows. Impor-
tantly, these pathways will likely provide unique interactions with
APC/C that can be targeted pharmacologically.
APC/CCdh1 IS REQUIRED FOR MITOTIC EXIT AND G1 MAINTENANCE
APC/CCdh1 targets multiple substrates for degradation during
mitosis (Figure 1). Foremost among these are the mitotic cyclins,
whose degradation ablates cyclin-dependent kinase 1 (CDK1)
activity (Brandeis and Hunt, 1996; Irniger and Nasmyth, 1997).
APC/C also reduces activity of multiple CDKs by initiating degra-
dation of two components of the SCF ubiquitin ligase, the F-box
protein Skp2 and an accessory protein, Cks1 (Bashir et al., 2004;
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FIGURE 1 | APC/CCdh1 regulates several cell cycle phases. (1, 2)
APC/CCdh1promotes mitotic exit and maintains G1-phase by inhibiting CDK
activity. (3) APC/CCdh1 needs to be inactivated for cells to enter S phase.
APC/CCdh1 promotes cell cycle exit to a quiescent state (4) or differentiation
(5). APC/CCdh1 induces differentiation of neurons, hematopoietic cells, lens
cells, and myocytes.
Wei et al., 2004). Degradation of these two substrates raises the lev-
els of the cyclin-dependent kinase inhibitors p27Kip1 and p21Cip1,
which are normally targeted for degradation in an SCFSkp2 and
Cks1 dependent manner (Ganoth et al., 2001; Bornstein et al.,
2003). CDK inhibitors associate with speciﬁc cyclins and CDKs,
preventing them from binding to ATP, and hence blocking their
catalytic activity. Thus, high p27Kip1 and p21Cip1 levels maintain
an early G1 state by reducing CDK activity. Another mechanism
to promote G1 by reducing CDK activity involves APC/CCdh1
mediated inhibition of an activator of S phase entry, cyclin D1.
APC/CCdh1 initiates degradation of the transcription factor Ets2
(Li et al., 2008),which normally controls cyclinD1 levels (Albanese
et al., 1995). Consistent with these ﬁndings, depletion of Cdh1 by
siRNA stabilizes Skp2 and Ets2, resulting in p21Cip1 and p27Kip1
degradation and cyclin D1 elevation in G1, followed by prema-
ture S phase entry (Wei et al., 2004; Li et al., 2008) and increased
proliferation (Bashir et al., 2004). Thus, APC/CCdh1 function dur-
ing mitotic exit is coupled to G1 maintenance. It initiates a sharp
decrease in CDK1 activity during mitotic exit by targeting the
mitotic cyclins for destruction and subsequently remains active
in early G1 to ensure that they remain inactive. In addition, it
ensures that other cyclin-dependent kinases, namely CDK2/cyclin
E, CDK2/cyclin A, CDK4/cyclin D, and CDK6/cyclin D are inac-
tive since it maintains high p27Kip1 levels and low cyclin D1 levels
through Skp2 and Ets2 degradation.
One question that immediately arises from these studies is that
if APC/C keeps CDKs inactive in early G1, how do cells eventu-
ally reach S phase. The answer lies in the multiple mechanisms
that decrease APC activity (Figure 1). For instance, the ubiquiti-
nation of the APC/C-speciﬁc ubiquitin-conjugating enzyme (E2)
UbcH10 by APC/CCdh1 provides a negative feedback mechanism
that eventually dampensAPC/CCdh1 activity (Rape and Kirschner,
2004; Rape et al., 2006). Further, Cdh1 is inactivated by both
phosphorylation and degradation (Lukas et al., 1999; Listovsky
et al., 2004; Benmaamar and Pagano, 2005). Finally, E2F activates
the transcription of the APC/C pseudo-substrate early mitotic
inhibitor-1 (Emi1)/Rca1 in late G1, which inhibits APC/CCdh1
activity (Hsu et al., 2002). These distinct mechanisms ensure that
APC/CCdh1 activity remains low from late G1 until the subsequent
metaphase when it is activated via reduction of CDK and Emi1
activity (Kotani et al., 1998; Hsu et al., 2002; Figure 1).
APC/CCdh1 CONTROLS PRE-REPLICATION COMPLEX FORMATION
One of the main reasons APC/CCdh1 activity must remain low
during S phase is that it is an inhibitor of pre-replication complex
formation required for S phase entry (Difﬂey, 2004). APC/CCdh1
controls the formation of the pre-replication complexes by mod-
ulating levels of three major regulators of the formation of the
complex: Orc1, Cdc6, and geminin. For DNA replication to pro-
ceed, cells need to alternate between periods of low CDK activity
and low geminin levels, in which the pre-replicative complexes
(preRCs) are assembled; and periods of high CDK activity and
high geminin levels in which origin ﬁring and DNA replication
occurs (McGarry and Kirschner, 1998; Petersen et al., 2000; Araki
et al., 2003). APC/CCdh1 is crucial to properly regulate the switch
between these two states. For instance,Orc1 andCdc6 are degraded
via APC/CCdh1 during early G1 (Petersen et al., 2000; Araki et al.,
2003). Further, geminin levels are tightly controlled byAPC/CCdh1.
Geminin prohibits initiation of DNA replication at inappropri-
ate times of the cell cycle by preventing MCM recruitment at
the replication origins. During G1 the APC/C is active and as a
consequence, geminin concentration is low. At the G1–S tran-
sition, APC/C is inactivated and geminin begins to accumulate.
However, geminin concentration is not sufﬁcient to inhibit a ﬁrst
wave of preRC formation and DNA replication begins. As S phase
progresses, geminin accumulates and inhibits subsequent recruit-
ment of MCMs to the replication origins (McGarry andKirschner,
1998), and therefore re-duplication is avoided (McGarry and
Kirschner, 1998; Wohlschlegel et al., 2000).
APC/CCdh1 PROMOTES CELL CYCLE EXIT AND QUIESCENCE
Multiple studies suggest that a major APC/CCdh1 function outside
of the cell cycle is limiting CDK activity required for cell cycle pro-
gression (Qiao et al., 2010). APC/CCdh1 regulates CDK inhibitors
that reduce CDK activity and initiate cell cycle exit. Adding a
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second layer of regulation to APC/CCdh1 activity, Binné et al.
(2007) connected retinoblastoma protein (pRb) to APC/CCdh1,
Skp2, and CDK inhibitor dependent cell cycle exit. These stud-
ies demonstrated that hypophosphorylated pRb associates with
the APC/C speciﬁcally when activated by Cdh1, thus promot-
ing Skp2 degradation and accumulation of p27Kip1 and p21Cip1.
This important ﬁnding linked extracellular signaling mecha-
nisms, which normally control pRb activity to APC/C dependent
degradation of Skp2 and initiation of cell cycle exit.
Once cells have exited the cell cycle, APC/C activity is required
to maintain quiescence or differentiation. For instance, APCCdh1
inactivation by deleting its Apc2 subunit in adult hepatocytes
induced these otherwise quiescent cells to re-enter the cell cycle
(Wirth et al., 2004). Similarly, APCCdh1 has also been proposed
to block postmitotic differentiated neurons from inappropriate
cycling and apoptosis (Almeida et al., 2005; Jackson, 2006).
APC/CCdh1 REGULATES CELL CYCLE EXIT AND CELL DIFFERENTIATION
APC/CCdh1 activity promotes cell cycle exit and differentiation
since Cdh1 depletion reduces differentiation of muscle, lens,
hematopoietic, andneuronal cells (Lasorella and Iavarone,2006; Li
et al., 2007; Wu et al., 2007; Garcia-Higuera et al., 2008). Although
our knowledge of the involvement of APC/CCdh1 in the differ-
entiation of other tissues awaits further investigation, its critical
function in the degradation of cell cycle proteins suggests it likely
plays relevant roles in linking quiescence and differentiation in
most cell types. Further, since cancer progression is often thought
to involve a dedifferentiation process (Daley, 2008; Trosko, 2009),
understanding APC/C’s involvement in normal cell cycle exit and
differentiation will give us clues as to how APC/C regulation or
substrate targeting may be misregulated during tumorigenesis.
Neuronal differentiation
Following a period of proliferation, neural progenitors differen-
tiate into postmitotic neurons. Since Cdh1 levels are (Gieffers
et al., 1999; Stegmuller and Bonni, 2005) higher in postmitotic
neurons relative to their neural progenitors (Yao et al., 2010),
APC/CCdh1 may play a role in neuronal cell cycle exit. Consis-
tent with this notion, an increase in APC/CCdh1 activity and a
decrease of APC/CCdh1 substrates has been observed during ter-
minal differentiation (Almeida et al., 2005; Yao et al., 2010). By
contrast,upregulationofAPC/CCdh1 substrates has beendescribed
in human neural tumors, suggesting that APC/CCdh1 activity is
attenuated under these conditions (Lasorella and Iavarone, 2006;
Eckerle et al., 2009).
Inhibitor of DNA binding 2
One of the targets that couples APC/CCdh1 activity with neuronal
differentiation is inhibitor of DNA binding 2 (Id2, also known
as inhibitor of differentiation 2). In the developing nervous sys-
tem, Id2 has been shown to inhibit the activity of neurogenic
basic helix–loop–helix (bHLH) transcription factors required for
neuronal differentiation (Yokota, 2001; Perk et al., 2005; Roth-
schild et al., 2006; Jung et al., 2010). APC/CCdh1 targets Id2 for
destruction, which couples cell cycle exit, differentiation, and
axonal growth during the differentiation of diverse neuronal types
(Lasorella and Iavarone, 2006; Yao et al., 2010). Thus, Id2 protein
downregulation via proteolysis is essential for neuronal differenti-
ation, suggesting that deregulationof Id2 destructionmayunderlie
neural tumors.
Deregulated Id2 expression prevents cell cycle arrest via a wide
range of signals (Lasorella et al., 2002; Kowanetz et al., 2004; Bagh-
doyan et al., 2005). Id2 downregulation via degradation allows the
bHLH transcription factor E47 levels to increase and subsequently
promote neural cell differentiation through induction of the CDK
inhibitor p57Kip2 in the developing mouse brain (Rothschild et al.,
2006; Tury et al., 2011). Similarly, decreasing Id2 levels increases
expression of known mediators of neuronal differentiation such as
Hes1 andAscl1 (Mash1) transcription factors (Havrda et al., 2008)
and NeuroD/E47 (Jung et al., 2010). Under certain experimental
conditions, ectopic Id2 is able to drive terminally differentiated
cells back into the cell cycle (Chaudhary et al., 2005). Importantly,
the observation that themost aggressive tumors frequently contain
the highest levels of Id proteins raises the possibility that deregu-
lating Id protein stability by APC/CCdh1 might also contribute to
Id accumulation in cancer.
Skp2
The APC/C substrate Skp2 controls the G1 to S transition by elim-
inating numerous regulatory proteins that inhibit S phase entry
(Reed, 2008). The SCFSkp2 target p27Kip1 plays a large role in cell
cycle exit and differentiation, particularly neuronal differentia-
tion (Durand et al., 1998; Vernon et al., 2003; Tarui et al., 2005;
Nguyen et al., 2006, 2007). Genetic disruption of p27Kip1 causes a
general increase in cell proliferation (Fero et al., 1996; Carruthers
et al., 2003), including neurogenesis in the cortex and spinal cord
(Nguyen et al., 2007; Li et al., 2009). Control of p27Kip1 is dual,
subject to the accumulation of both cyclin-CDK complexes,which
promote its phosphorylation, and Skp2, which promote the ubiq-
uitination of phosphorylated p27Kip1 (Carrano et al., 1999; Mon-
tagnoli et al., 1999). Harmey et al. (2009) described an essential
role for APC/CCdh1 in cerebellar granule progenitors by mediating
Skp2 destruction, thus coordinating cell cycle exit and termi-
nal differentiation. Similar studies uncovered APC/CCdh1–Skp2
dependent differentiationof human embryonic stemcells (Bar-On
et al., 2010). Collectively, these data suggested that twowell-known
inducers of neuronal differentiation, nerve growth factor (NGF),
and retinoic acid, hyperactivate APC/CCdh1. NGF rapidly induced
APC/CCdh1 activity and promoted degradation of APC substrates,
including cyclin B1 and the F-box protein Skp2 (Harmey et al.,
2009). Similarly, retinoic acid promoted neuronal differentiation
through increasing APC/CCdh1 activity (Cuende et al., 2008; Yao
et al., 2010). Further, retinoic acid induced nuclear accumulation
of Cdh1, enhancing APC/CCdh1 activity, Skp2 destabilization, and
p27Kip1 accumulation (Cuende et al., 2008) by reducing expression
of Rae1, a nuclear export factor that limits APC/CCdh1 activ-
ity in mitosis (Yao et al., 2010). Similar to NGF and retinoic
acid, bone morphogenetic protein 2 (BMP2) promotes cell cycle
arrest via downregulation of Skp2 and accumulation of p27Kip1
in a neuroblastoma cell line (Nakamura et al., 2003). Thus, Skp2
degradation via APC/CCdh1 is linked to neuronal differentiation
and various signaling pathways. Disruption of signaling pathways
controlling the APC/C–Skp2 axis during neuronal differentia-
tion may lead to disruption of homeostasis. Consistent with this
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possibility, reduced Skp2 and cyclin B1 expression has been seen
in a transgenic model of Down syndrome where alteration of cell
cycle rate and reduction of neurogenesis in the cerebellum was
described (Contestabile et al., 2009). Moreover, Skp2 transcript
levels gradually increase with the aggressiveness of neuroblastoma
subtype (Westermann et al., 2007), making the regulation of Skp2
by APC/CCdh1 an attractive target in tumorigenesis.
Muscle cell differentiation
Myogenesis is a multistep process that sequentially requires
the proliferation of committed myoblasts, the differentiation
of myoblasts into postmitotic myocytes, and ﬁnally fusion of
myocytes to formamultinucleatedmyotubewith contractile capa-
bility. In muscle, APC/CCdh1 drives cell differentiation through
the destruction of two proteins, Skp2 and Myf5 (Li et al., 2007;
Figure 1). Elimination of Skp2 leads to the accumulation of the
CDK inhibitors p21Cip1 and p27Kip1 in myoblasts, allowing cell
cycle withdrawal. Consistent with a role of p21Cip1 in myotube
formation, mice lacking p21Cip1 fail to form myotubes (Zhang
et al., 1999). Thus, the APC/C–Skp2–p21Cip1/p27Kip1 axis is likely
to be essential for muscle development.
Coupled to APC/C mediated destruction of Skp2 in muscle is
APC/C targeting of Myf5. Myf5 is a bHLH transcription factor
that regulates myoblast proliferation and homeostasis (Gayraud-
Morel et al., 2007). Its expression is restricted to dividing and
undifferentiated cells. Myf5 is not directly involved in the deci-
sion to differentiate per se but in Myf5 null animals, differentia-
tion is delayed during early regeneration and Myf5 null mutants
are characterized by a subtle progressive myopathy and muscle
regeneration deﬁcits (Gayraud-Morel et al., 2007). Degradation
of Myf5 by APC/CCdh1 facilitates myogenic fusion, a process
required formyoblast differentiation (Gayraud-Morel et al., 2007).
Importantly, impaired degradation of both Skp2 and Myf5 seems
to have a role in muscle cancer since overexpression of Skp2
and Myf5 are found in cervical carcinoma and rhabdomyosar-
comas, respectively (Tamamori-Adachi et al., 2004; Zibat et al.,
2010).
Lens cell differentiation
Proper lens differentiation requires precise temporal control of
the cell cycle and the coordination of cell cycle exit with differ-
entiation cues and signaling pathways (Zhu and Skoultchi, 2001).
APC/CCdh1 has been identiﬁed as a crucial regulator of lens dif-
ferentiation that induces SnoN degradation (Wu et al., 2007).
SnoN, a critical transcriptional corepressor of the TGF-β path-
way, has been proposed to be a functional switch controlling
the expression of p15 and p21Cip1 (Zhu et al., 2005). p21Cip1
and p15 are two essential cell cycle inhibitors that contribute to
cell cycle arrest via downregulation of cyclin D/CDK4/6 activity
(Reynisdottir et al., 1995). The upregulation of the p21Cip1 and
p15 inhibitors is necessary for coupling cell cycle withdrawal in
response to TGF-β signaling and the initiation of lens differentia-
tion. Moreover, Cdh1 depletion was shown to attenuate induction
of p15 and p21Cip1 and signiﬁcantly block lens differentiation (Wu
et al., 2007). Impaired regulation of SnoN has not been related to
corneal tumors but given the importance of APC/CCdh1 in lens
differentiation, further studies could open new potential targets in
these carcinomas.
Hematopoietic cell differentiation
Hematopoiesis gives rise to all blood cells through a complex series
of proliferation and differentiation events that occur through-
out lifespan (Kawamoto et al., 2010). The hematopoietic system
consists of a large array of differentiated blood cells including
erythrocytes and cells of the myeloid and lymphoid lineages. Evi-
dence supporting a role for APC/CCdh1 in hematopoiesis comes
fromCdh1knockoutmice.Cdh1heterozygousmicedevelopB-cell
lymphoma and myelodysplastic disorder (Garcia-Higuera et al.,
2008). Although howAPC/CCdh1 regulates hematopoiesis remains
to be investigated, targeted degradation of Id protein could be
one mechanism (Figure 1). While Id proteins are downregulated
during cell cycle exit, overexpression of Id proteins in terminally
differentiated cells triggers cell cycle re-entry. Id proteins mod-
ulate cellular proliferation and differentiation in hematopoietic
cells (Perk et al., 2005). Id1 is essential for hematopoietic stem cell
maintenance and hematopoietic development (Perry et al., 2007)
and the balance between Id1 and E-protein regulates myeloid-
versus-lymphoid lineage commitment (Cochrane et al., 2009).
Dysfunction of Id2 in mice or cultured cells induces lymphoid
differentiation, whereas Id2 overexpression inhibits lymphoid and
myeloid differentiation (Perk et al., 2005; Ji et al., 2008). Further-
more, in addition to an Id1 and Id2 requirement for the pro-
liferation and differentiation of hematopoietic precursors, these
factors may contribute to the development of myeloid malignan-
cies through enhanced proliferation or inhibited differentiation
(Perk et al., 2005).
APC/CCdh1 PRESERVES CHROMOSOME INTEGRITY
Loss of Cdh1 function produces precocious initiation of DNA
synthesis, leading to lower S phase progression, which results
in stalled replication forks and under-replicated DNA (Garcia-
Higuera et al., 2008). These replicative defects, as well as the
upregulation of mitotic kinases, can ultimately lead to genetic
damage (Garcia-Higuera et al., 2008; Cotto-Rios et al., 2011).
Cdh1-deﬁcient cells exhibit defects in mitotic exit and cytokine-
sis and accumulate a variety of genomic aberrations (Engelbert
et al., 2008;Garcia-Higuera et al., 2008). Such genomic aberrations
may be a consequence of the inability of APC/CCdh1 to properly
mediate a response to DNA damage in Cdh1 null cells. In G1,
APC/CCdh1 targets the ubiquitin speciﬁc protease USP1 for pro-
teasome dependent degradation (Cotto-Rios et al., 2011). Since
USP1 counteracts monoubiquitination of the DNA repair protein
proliferating cell nuclear antigen (PCNA), APC/CCdh1 dependent
USP1 destruction allows a permissive environment during G1 for
PCNA monoubiquitination, which is required for UV-mediated
DNA gap repair (Cotto-Rios et al., 2011). In addition to USP1,
APC/CCdh1 controls the levels of multiple proteins involved in
the DNA damage checkpoint response and DNA repair includ-
ing Claspin, Rad17, thymidine kinase 1, and the ribonucleotide
reductase subunit (Chabes et al., 2003; Ke et al., 2005; Bassermann
et al., 2008; Gao et al., 2009a; Zhang et al., 2010). During G2, the
APC/CCdh1 substrate polo-kinase 1 (Plk1) controls CDK1 activa-
tion and recovery from DNA replication stresses (Watanabe et al.,
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2004; Mamely et al., 2006). Cells exposed to genotoxic stress in G2
need to arrest the cell cycle and repair damaged DNA. One mecha-
nism to achieve this is to reduce levels of proteins such as Plk1 and
mitotic cyclins, which are required for mitotic entry. Although
normally inactive during G2, APC/CCdh1 is activated via Cdh1
dephosphorylation during genotoxic stress, which is mediated by
theCdc14Bphosphatase (Bassermann et al., 2008). Therefore,par-
ticipation of APC/CCdh1 in the G2 DNA damage response suggests
another mechanism for genomic instability observed in Cdh1 null
cells.
APC/CCdh1 MODULATORS AS TUMOR SUPPRESSOR
PROTEINS OR ONCOGENES
Considering the prominent role of APC/C in cell cycle regula-
tion and genomic stability, it is tempting to speculate that its
dysregulation triggers a major perturbation of cell cycle progres-
sion and contributes to cell transformation. In fact, hemizygous
frameshift and point mutations in several subunits of APC/C
have been found in colon cancer cell lines and tumors (Wang
et al., 2003). Mutations in Apc3, Apc6, and Apc8 were found
in colon cancer, breast cancer, neuroblastoma, hepatocarcinoma,
melanoma, glioma, choriocarcinoma, endometrial cancer, ovarian
cancer, and prostate carcinoma (Wang et al., 2003). Overexpres-
sion studies of Apc8 suggested that APC/C mutations can act in a
dominant-negative manner to inhibit its function and cause inap-
propriate cell cycle progression (Wang et al., 2003). Moreover, the
APC/C cofactor Cdh1 has been described as a tumor suppres-
sor (Garcia-Higuera et al., 2008). Knockdown or inhibition of
Cdh1 is associated with centrosome ampliﬁcation and chromo-
somemis-segregation, and is implicated in genomic instability and
tumorigenesis (Ross and Cohen-Fix, 2003; Wasch and Engelbert,
2005; Engelbert et al., 2008; Garcia-Higuera et al., 2008). Cdh1-
deﬁcient mice display genomic instability and heterozygous Cdh1
mice develop epithelial tumors, such asmammary gland adenocar-
cinomas and ﬁbroadenomas, which are not observed in wild-type
mice. Furthermore, these tumors contain one Cdh1 wild-type
allele, suggesting that Cdh1 is haploinsufﬁcient for tumor sup-
pression. In addition to mutations in APC/C or Cdh1 subunits,
it is tempting to speculate that alterations of APC/C upstream
regulators may lead to transformation (Table 1).
RETINOBLASTOMA PROTEIN
A well-established tumor suppressor protein that positively regu-
latesAPC/C activity is the pRB. pRBplaysmultiple roles during the
cell cycle; it blocks cell cycle progression from G1 to S phase, and
guards the cell fromreplicating damagedDNA, thus preventing the
integration of mutations into the genome. This tumor suppressor
function requires binding and repressing the E2F family tran-
scription factors (Classon and Harlow, 2002; Chen et al., 2009).
Reversion of the pRb–E2F interaction occurs after mitogenic stim-
uli sufﬁcient for the activation of CDKs that phosphorylate pRB
in the nucleus. Subsequently, phospho-pRb is released from E2Fs,
which can then induce S phase entry (Thoma et al., 2011). Consis-
tent with a direct inhibitory role in S phase entry, loss of various
pRBs leads to unscheduled cell proliferation in many tissues (Vidal
and Koff, 2000; Cobrinik, 2005; Marx et al., 2010). Accordingly,
mutations in Rb are found in a wide variety of cancers mainly
in the lung, breast, and eye (Meraldi et al., 1999; Sabado Alvarez,
2008).
Retinoblastoma protein also possesses E2F-independent func-
tions that contribute to cell cycle control. pRB interacts with both
Skp2 (Ji et al., 2004) and with APC/CCdh1 through distinct sur-
faces (Binné et al., 2007). pRB needs to interact with both proteins
to target Skp2 for ubiquitin-mediated degradation and promote
p27Kip1 accumulation and cell cycle exit. Interestingly, similar to
E2F1, Cdh1 only interacts with the hypophosphorylated (active)
form of pRb, and phosphorylation of pRb by cyclin A/CDK2
kinase abolished the ability of Rb to interact with both Cdh1
and E2F1. Therefore Cdh1, by competing with pRb interaction,
can also regulate the activity of the E2F1 transcription factor
(Sorensen et al., 2000; Gao et al., 2009a). Further, given that both
pRB and Cdh1 have tumor suppressive functions, whether the
pRB–APC/CCdh1 interaction ismisregulatedduring tumorigenesis
should be investigated (Figure 2).
PTEN
Recent studies have demonstrated that the well-characterized
tumor suppressor protein PTEN is a positive regulator of APC/C
activity. PTEN (Cairns et al., 1997; Steck et al., 1997; Feilotter et al.,
1998; Gray et al., 1998; Li and Sun, 1998) encodes a lipid phos-
phatase, which plays a crucial role in adhesion, migration, growth,
and apoptosis. Pten-null mice die embryonically, but heterozy-
gous mice survive and develop tumors in the lymphoid system,
endometrium,prostate, and the thyroid (Di Cristofano et al., 1998;
Podsypanina et al., 1999). Pten somatic mutations occur in a large
percentage of human cancers, with the highest numbers found in
endometrial, central nervous system, skin, and prostate cancers
(Chalhoub and Baker, 2009).
The effects observed after PTEN loss have been attributed to
activation of the PI3K/AKT pathway as PTEN can dephosphory-
late phosphoinositide-3,4,5-triphosphate (PIP3), a potent activa-
tor of Akt1 (Maehama and Dixon, 1998). PTEN inactivation by
phosphorylation or oxidation in human cancer results in elevated
Akt1 activity and abnormal growth regulation (Silva et al., 2008;
Chalhoub andBaker, 2009;McCubrey et al., 2011).However, func-
tions independent of its phosphatase activity have been described
(Maier et al., 1999; Georgescu et al., 2000; Koul et al., 2002a,b;
Gildea et al., 2004; Blanco-Aparicio et al., 2007). Recently, a novel
interaction between PTEN and APC/CCdh1 has been reported
(Song et al., 2011). Song et al. (2011) demonstrated that nuclear
PTEN directly enhances the activity of APC/C by promoting its
association with Cdh1 in a phosphatase-independent manner.
Conversely, PTEN loss impairs the activity of theAPC/CCdh1 com-
plex. Therefore, loss of PTEN function decreasesAPC/CCdh1 activ-
ity, suggesting novel molecular pathways that may be involved in
the progression and initiation of tumorigenesis. This in turn high-
lights the complexity of the dose-dependent tumor promoting
and fail-safe cellular responses evoked by PTEN loss. Accordingly,
tumor-derived mutations that do not affect the phosphatase enzy-
matic activity of PTEN in vitro have also been identiﬁed. These
were found to affect the compartmentalization of PTEN in the
cell, either by sequestering PTEN in the nucleus (Denning et al.,
2007) or by interfering with PTEN’s recruitment to the plasma
membrane (Lee et al., 1999; Georgescu et al., 2000; Walker et al.,
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Table 1 | Modulators of APC/CCdh1 dysregulated in cancer.
APC/C
regulator
Effects on APC/C Major cell
cycle function (s)
Role in tumorigenesis Relevant cancers Relevant reference
PTEN Activator. Promotes the
interaction between
APC/C and Cdh1
Promotes cell
differentiation.
Downregulation
promotes cell
proliferation
Acts as a tumor
suppressor. Null mice die
and heterozygous develop
tumors
Lymphoid system,
endometrium, thyroids,
central nervous system,
skin, prostate, breast
Chalhoub et al. (2009),
Hollander et al. (2011),
Song et al. (2011), Uddin
et al. (2004), Kwon et al.
(2008)
pRB Activator. Promotes
degradation of Skp2 by
interaction with APC/C
and Skp2
Blocks progression of
G1/S. Downregulation
promotes cell
proliferation
Acts as a tumor
suppressor. Prevents
integration of DNA damage
Lung, breast, eye Chen et al. (2009), Clas-
son and Harlow (2002),
Ji et al. (2004), Binné
et al. (2007), Sabado
Alvarez (2008)
Sirt2 Activator. Acetylates
Cdh1 and Cdc20
promoting their
interaction with APC/C
Regulates
chromosomal
condensation during
mitosis. Maintains
genome integrity
Acts as a tumor
suppressor. Decrease of
function promotes
genome instability
Breast, liver, brain,
kidney, and prostate
cancers
North and Verdin (2007),
Kim et al. (2011)
PSMA Activator. Associates
with Cdc27
Unknown Acts as an oncogene.
Overexpression promotes
premature activation of
APC/C and aneuploidy
Prostate cancer Rajasekaran et al.
(2005, 2008), Burger
et al. (2002), Chang
et al. (1999, 2001)
Emi1 Inhibitor. Binds to
APC/C
Permits accumulation
of cyclins in G1/S
Overexpression with p53
knock down promotes
proliferation and
chromosomal instability
Kidney, liver, lung,
endometrium, lymphoid
system, ovarium, lung
Hsu et al. (2002), Miller
et al. (2006), Lehman
et al. (2006), Gütge-
mann et al. (2008)
MAK Inhibitor.
Phosphorylates Cdh1
Promotes stabilization
of APC/CCdh1
substrates
Acts as an oncogene.
Overexpression promotes
extra-centrosomes
Prostate cancer Wang and Kung (2011)
FIGURE 2 | Dysregulation of APC/CCdh1 modulators can promote cancer.
Decreasing expression of the tumor suppressors pRB, PTEN, and Sirt2 may
promote APC/CCdh1 inactivation, leading to cell proliferation and tumorigenesis.
pRB downregulation may decrease Skp2 destruction. Decreasing PTEN levels
might reduce APC/C activity. Decrease of Sirt2 could enhance the acetylation
of the coactivators Cdh1 and Cdc20, lowering the capacity to interact with
APC/C. In addition to the tumor suppressors, the oncogenes Emi1, PSMA,
and MAK also regulate APC/CCdh1 activity. Emi1 binds as a pseudo-substrate
and leads to APC/C inactivation. PSMA and MAK increase APC/CCdh1 activity
and produce genomic instability.
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2004), thus possibly negatively impacting the PTEN–APC/CCdh1
interaction. Consistent with this possibility,APC/CCdh1 substrates
are overexpressed in tumors containing PTEN deﬁciency (Marino
et al., 2002;Gao et al., 2009a; Liu et al., 2011b). Further,PTENover-
expression has been found to suppress tumorigenesis by inducing
G1 cell cycle arrest in human glioblastoma cells (Li and Sun, 1998).
Given the importance of PTEN and APC/CCdh1 for cancer pro-
gression, it will be crucial to determinewhether tumors containing
PTENmisregulation have both hyeractivation of theAkt1 pathway
and dysregulation of APC/CCdh1 function (Figure 2).
EARLY MITOTIC INHIBITOR-1
The Emi1 is an APC/C inhibitor, which is overexpressed in mul-
tiple tumors. Emi1 is a key cell cycle regulator that is required
for accumulation of mitotic cyclins and other critical cell cycle
regulators during S phase and G2 (Hsu et al., 2002). At the G1/S
transition, Emi1 functions as a pseudo-substrate inhibitor of the
APC/C (Miller et al., 2006), allowing substrates to accumulate
(Guardavaccaro et al., 2003; Miller et al., 2006). In early mito-
sis, Emi1 is phosphorylated by Plk1 (Hansen et al., 2004), which
triggers SCFβTrCP-dependent ubiquitination and destruction, thus
inducing APC/C activation and mitotic progression (Margottin-
Goguet et al., 2003). Emi1 overexpression leads to unscheduled
cell proliferation, tetraploidy, and chromosomal instability in p53-
deﬁcient cells (Lehman et al., 2006; Figure 2). In p53 wild-type
cells, the induction of tetraploidy and aneuploidy by overex-
pressing APC/C inhibitors like Emi1 typically leads to G1 arrest
or apoptosis. Indeed, Emi1 overexpression causes mitotic cata-
strophe and genomic instability through APC/C misregulation,
and thus potentially contributes to tumorigenesis (Hsu et al.,
2002). Upregulation of Emi1 mRNA has been found in a variety
of malignant tumors compared to matched normal and benign
tumor tissue. Notably, Emi1 protein is highly expressed in renal
cell carcinomas, cervical adenocarcinomas, hepatocellular car-
cinomas, oligodendrogliomas, lung adenocarcinomas, endome-
trial cancers, of melanomas, many lymphomas and ovarian clear
cell carcinoma (Lehman et al., 2006; Gütgemann et al., 2008).
Emi1 expression is also related to the pRB/E2F pathway since
Emi1 is a target of the E2F transcription factor. At the G1-S
transition Emi1 is transcriptionally induced by E2F, thus accel-
erating S phase entry (Hsu et al., 2002). The importance of
this regulation is underscored by the ﬁnding that lack of pRb
repression of E2F-mediated transcription causes misregulation of
Emi1 and APC/C substrates in malignant tumors (Lehman et al.,
2006).
Sirt2
Recently, the histone deacetylase (HDAC) SIRT2 has been shown
to positively regulate APC/C activity (Kim et al., 2011). Histone
acetyltransferases (HATs) and HDACs are enzymes controlling
protein acetylation. Both target histones, whereas HATs catalyze
the acetylation of histones and relax chromatin to increase acces-
sibility of transcription factors to promoters of target genes,
HDACs remove acetyl groups from histones and repress transcrip-
tion (Strahl and Allis, 2000). Most of them have been found in
transcription factor complexes and, therefore, have been consid-
ered to regulate transcription by modulating acetylation levels of
chromatin (Kuo and Allis, 1998; Kouzarides, 1999). HDACs are
important for cell cycle progression and their inhibition promote
cell arrest in G1 and G2 (Marks et al., 2001; Johnstone and Licht,
2003; Noh and Lee, 2003). HDACs also have an important role in
heterochromatin formation and maintenance (Olsson et al., 1999;
Taddei et al., 2001) and are implicated in chromosome segregation
(Nakayama et al., 2003; Silverstein et al., 2003; Kimata et al., 2008).
Several HDACs have a role in tumorigenesis, acting as a sup-
pressors or promoters (Lagger et al., 2002; Glaser et al., 2003;
Saunders and Verdin, 2007; Wang et al., 2008a,b; Deng, 2009; Bell
et al., 2011; Kim et al., 2011) and HDAC inhibitors are a promis-
ing class of anti-cancer agents (Johnstone and Licht, 2003; Yoshida
et al., 2003; Bolden et al., 2006). SIRT2 is predominantly localized
in the cytoplasm where it deacetylates microtubules (North et al.,
2003). During mitosis, SIRT2 is localized to chromosomes reg-
ulating chromosomal condensation (Vaquero et al., 2006; Inoue
et al., 2007), and is also associated with mitotic structures, includ-
ing the centrosome, mitotic spindle, and midbody, presumably
to ensure normal cell division (North and Verdin, 2007). Kim
et al. (2011) demonstrated that SIRT2 regulates APC/C activ-
ity through deacetylation of its coactivators Cdh1 and Cdc20.
Deacetylation of Cdh1 and Cdc20 by SIRT2 enhances the inter-
action of these coactivators with Cdc27, leading to activation of
APC/C. In Sirt2 mutant mice, reduced APC/C activity results
in tumor formation by producing genomic instability associ-
ated with centrosome ampliﬁcation, aneuploidy mitotic cell death,
and spontaneous tumor formation. These deﬁciencies seem to be
caused by a combined effect of altered expression of mitotic regu-
lators that are controlled byAPC/C (Figure 2). Accordingly, SIRT2
expression is reduced in several human malignancies includ-
ing breast, liver, brain, kidney, and prostate cancers (Kim et al.,
2011).
PSMA AND MAK
Mitotic defects associatedwith chromosomal aberrations are often
observed in prostate cancer cells and tissue, suggesting possible
misregulation by APC/C (Tribukait, 1991; Beheshti et al., 2001;
Pihan et al., 2001). Two regulators of the APC/C have been
found to be clearly involved in prostate cancer, prostate spe-
ciﬁc membrane antigen (PMSA) and male germ cell-associated
kinase (MAK). PSMA is a type II transmembrane protein that
exhibits both N -acetylated alpha-linked acidic peptidase (NAAL-
ADase) and folate hydrolase activities (Ghosh and Heston, 2004;
Rajasekaran et al., 2005). PSMA is localized to secretory cells
within the prostatic epithelium although its physiological and
pathological functions remain unclear. PSMA is upregulated in
advanced prostate carcinoma and metastatic disease (Rajasekaran
et al., 2005), and is a feature of practically every prostatic tissue
examined (Rajasekaran et al., 2005,2008). PSMA is absent ormod-
erately expressed in hyperplastic and benign tissues, while malig-
nant tissues have high levels, demonstrating that PSMA expression
increases proportionally to tumor aggressiveness (Troyer et al.,
1995; Kawakami and Nakayama, 1997; Liu et al., 1997; Silver
et al., 1997; Sweat et al., 1998; Chang et al., 1999, 2001; Burger
et al., 2002; Ross et al., 2003). PSMA is localized to a mem-
brane compartment in the vicinity of centrosomes at the spindle
poles and associates with the APC/C subunit Cdc27 leading to
Frontiers in Oncology | Molecular and Cellular Oncology January 2012 | Volume 1 | Article 60 | 8
Penas et al. APC/C role in cancer
premature activation of APC/C, and induction of aneuploidy
(Rajasekaran et al., 2008). Increased APC/C activity observed
in PSMA expressing cells is sufﬁcient to impair the mitotic
spindle checkpoint, which agrees with the ﬁnding that PSMA
expressing cells exit mitosis prematurely (Figure 2). Therefore,
PSMA may have a causal role in the progression of prostate
cancer.
Male germ cell-associated kinase belongs to a protein kinase
family characterized by a catalytic domain resembling a hybrid
of the TXY motif found in mitogen-activated protein kinases
(MAPK) and the TY motif in CDKs (Payne et al., 1991; Brown
et al., 1999; Xia et al., 2002; Fu et al., 2005). MAK expression
is elevated in castration-resistant prostate cancer cell lines and
is generally overexpressed in prostate tumors, thus possibly con-
tributing to malignancy via aberrant regulation of mitosis (Wang
and Kung, 2011). MAK protein has a dynamic subcellular local-
ization during the cell cycle: it is localized to the mitotic spindle
and centrosomes during metaphase and anaphase, and to the
mitotic midbody from anaphase to telophase. MAK negatively
regulates APC/CCdh1 through interaction and phosphorylation
of Cdh1 in CDK phosphorylated sites, in a manner reminis-
cent of CDK-dependent inactivation of Cdh1 (Wang and Kung,
2011; Figure 2). The phosphorylation of MAK increases between
S and G2, peaks at early mitosis, and drastically decreases at
the end of mitosis. This promotes the dissociation of Cdh1 and
APC/C thus decreasing APC/CCdh1 activity and promoting the
stabilization of the substrates Aurora kinase A and Plk1. As over-
expression of Aurora-A is known to induce centrosome ampli-
ﬁcation (Zhou et al., 1998), the extra-centrosomes observed in
MAK overexpressed cells is likely due to cellular accumulation of
Aurora-A.
APC/C SUBSTRATES IN CANCER
Many APC/C substrates have been implicated in a variety of
human cancers (Table 2). For those substrates that are over-
expressed in cancer it is important to note that overexpression
of an APC/C substrate inﬂuences degradation of other APC/C
substrates (Rape and Kirschner, 2004), suggesting that global esti-
mates of APC/C substrate levels are required in normal and disease
states. Further, while there are arguably many APC/C substrates
that may be important for cancer progression, classifying their
relative importance and druggability is essential.
NIMA-RELATED KINASE 2
The proteolysis of APC/C substrates starts as cells make the transi-
tion from G2 to M phase. One of the earliest targets is the NIMA-
related kinase 2 (Nek2) family of serine/threonine protein kinases.
They are implicated in the regulation of centrosome separation
and spindle formation. Nek2A, along with cyclin A are unique
APC/CCdc20 substrates that get degraded during prometaphase
even when the SAC is active. A C-terminal dipeptide methionine–
arginine (MR) tail enables Nek2A to directly bind the APC/C
independently of Cdc20 (Hayes et al., 2006). Nek2 levels are upreg-
ulated in human breast cancer, pediatric osteosarcoma, and B-cell
lymphomas (Wai et al., 2002; de Vos et al., 2003; Hayward et al.,
2004).
CELL DIVISION CYCLE PROTEIN 20
Cell division cycle protein 20 is an essential coactivator of the
APC/C during mitosis. Multiple studies have indicated that main-
taining appropriate Cdc20 levels is important for cellular home-
ostasis. When this is disturbed and Cdc20 is overexpressed,
tumorigenesis can occur. For instance, oral squamous cell carci-
nomas (OSCC) and breast cancer cells overexpress Cdc20 causing
premature anaphase and aneuploidy linked to tumor formation
(Yuan et al., 2006;Mondal et al., 2007). Importantly, even a twofold
overexpression of Cdc20 leads to spindle checkpoint defects and
early Pds1 (securin) destruction producing aneuploidy (Pan and
Chen, 2004).
One of the major ways Cdc20 protein levels are controlled is
via the SAC. When the SAC is active during metaphase, the check-
point proteins Mad2, BubR1, and Bub3 bind to Cdc20 and convert
it into a substrate of APC/CCdc20. This allows for the ubiquitina-
tion anddegradationof Cdc20 byAPC/CCdc20 (Nilsson et al., 2008;
Ge et al., 2009). Thus, SAC activation inhibits Cdc20 and arrests
cells in metaphase. Inactivation of SAC at the end of metaphase
relieves this inhibition andCdc20promotesmitotic exit by degrad-
ing key substrates such as the mitotic cyclins. The importance of
SAC dependent control of Cdc20 levels is underscored by the ﬁnd-
ing that anti-mitotic cancer drugs that activate the SAC cause cell
cycle arrest. These drugs cause a prolonged metaphase arrest that
may eventually lead to cell death. However, during this prolonged
metaphase arrest, some Cdc20 escapes inhibition by the SAC and
as a result, cyclin B1 levels start to fall and cells exit mitosis, thereby
initiating mitotic slippage (Nilsson, 2011). This may be especially
true in some cancer subtypes since the frequency of mitotic slip-
page is hastened in tumor cells lacking p53 and pRb (Depamphilis,
2011). Further, mitotic slippage reduces the sensitivity of tumor
cells to chemotherapeutics. Thus, alternative means of inhibiting
Cdc20 are needed.
Recent evidence suggests that targeting Cdc20 directly could
be a better alternative than targeting the SAC in cancer therapy
(Huang et al., 2009; Manchado et al., 2010). Knockdown of Cdc20
by siRNA induces mitotic arrest and apoptosis in various cancer
cell lines that are otherwise resistant to apoptosis and prone to
mitotic slippage (Huang et al., 2009). Further, genetic ablation of
the Cdc20 gene in murine skin tumor and aggressive ﬁbrosarcoma
models results in complete tumor regression (Manchado et al.,
2010). Cdc20 deletion induces metaphase arrest and apoptosis in
tumor cells both in vitro and in vivo. Importantly, the activities
of Cdk1 and Mast1 kinases are required for this arrest. When
Cdk1 and Mast1 kinases are inhibited,Cdc20 null cells exit mitosis
via the activities of the phosphatases PP2A/B55α and PP2A/B55δ
(Manchado et al., 2010). Thus, small molecules attenuating Cdc20
coupled with those inhibiting these phosphatases may be effective
therapeutically.
GEMININ
Another APC/C substrate degraded at the metaphase–anaphase
transition is geminin. It is a small 25 kDaprotein that inhibitsDNA
re-replication during S phase. Geminin levels accumulate during
S, G2, and early mitosis. It suppresses the DNA replication factor
CDT1 that is required for the formation of preRCs. Depletion of
geminin by siRNA in tumor cells leads to DNA re-replication, cell
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cycle arrest, and apoptosis. However, regulation of CDT1 by gem-
inin is found to be rate limiting for initiation of DNA replication
only in cancer cells and not in normal or immortalized cells. Nor-
mal cells show the same effect only when cyclin A is co-depleted
with geminin (Zhu and Depamphilis, 2009). Thus it has been pro-
posed that inhibition of geminin activity can be used to selectively
kill cancer cells (Zhu and Depamphilis, 2009).
POLO-LIKE KINASE 1
Toward the end of anaphase, the pro-mitotic regulatory kinase
Plk1, is degraded by APC/CCdh1 in a D-box dependent manner
(Lindon and Pines, 2004). Plk1 is a major kinase in eukary-
otic cells involved in a variety of processes such as activation of
the maturation promoting factor (MPF) by phosphorylation of
Cdc25C and cyclin B1, bipolar spindle formation, and matura-
tion of the centrosome (Ohkura et al., 1995; Lane and Nigg, 1996;
Abrieu et al., 1998; Qian et al., 1998; Eckerdt et al., 2005). Elevated
Plk1 levels are present in a broad spectrum of cancers includ-
ing breast cancer, colorectal cancer, ovarian cancer, melanomas,
pancreatic cancer, prostate cancer, lung cancer, and squamous cell
carcinomas of the head and neck (Wolf et al., 1997, 2000; Knecht
et al., 1999; Strebhardt et al., 2000; Macmillan et al., 2001; Gray
et al., 2004; Weichert et al., 2004). This broad range of expres-
sion makes Plk1 a prime target in cancer (Strebhardt and Ullrich,
2006).
AURORA-A
Another APC/CCdh1 substrate during late mitosis is Aurora-A
(STK15/BTAK), a serine/threonine kinase localized to the cen-
trosome controlling mitotic spindle assembly and centrosome
maturation. It is involved in a variety of human cancers (Bischoff
et al., 1998; Zhou et al., 1998; Sen et al., 2002; Mondal et al.,
2007). Ectopic expression of Aurora-A leads to chromosome insta-
bility and centrosome ampliﬁcation (Miyoshi et al., 2001). One
way it achieves this is by phosphorylating and regulating Centrin,
the calcium-binding phosphoprotein located in the centrosome.
Phosphorylated Centrin is more stable against APC/CCdh1 medi-
ated destruction and an excess of it is thought to promote centro-
some ampliﬁcation in cancer (Lukasiewicz et al., 2011). Aurora-A
itself becomes resistant toAPC/CCdh1 mediated degradation when
it is constitutively phosphorylated on Ser 51, and consequently gets
overexpressed in head and neck cancers (Kitajima et al., 2007).
HIGH EXPRESSION IN CANCER 1
High expression in cancer 1 (HEC1), a recently identiﬁed
APC/CCdh1 substrate, is part of the NDC80 complex controlling
kinetochoremicrotubule dynamics. HEC1 levels peak during early
mitosis and fall by telophase (Lipkowitz andWeissman, 2011). The
mitotic regulatory kinase Nek2 phosphorylates HEC1 on Ser 165
thus activating it during G2/M. Inactivation of HEC1 results in
severe chromosome segregation defects (Chen et al., 1997, 2002;
Zheng et al., 1999). HEC1 is considered as a candidate marker for
breast lesions likely to undergo malignant transformation because
it is signiﬁcantly overexpressed in benign breast tumors (Bieche
et al., 2011). A small molecule called INH1, which binds to HEC1
and speciﬁcally disrupts the HEC1–Nek2 interaction, is found to
suppress human breast cancer cell proliferation in culture as well
as tumor growth in nudemice bearing xenografts (Wu et al., 2008).
c-Jun NH2-TERMINAL KINASE
c-Jun NH2-terminal kinase (JNKs), a class of MAPK, lead the cell’s
response to stress stimuli such as heat shock, radiation, and cyto-
toxic and genotoxic stress. Recently, nuclear JNK was found to be
a substrate of APC/CCdh1 during late mitosis and G1 (Gutierrez
et al., 2010a). JNK, in turn, controls APC/CCdh1 by phosphorylat-
ing Cdh1 at three residues (Yu et al., 1998; Summers et al., 2008) to
prevent premature Cdh1 association with the APC/C during G2.
JNK-induced phosphorylation of key regulators not only controls
cell survival and differentiation, but also cell cycle progression.
JNK phosphorylates Cdc25C at Ser 168 in G2, downregulating
its phosphatase activity required for CDK1 activation (Gutierrez
et al., 2010b). This is required for the correct timing of mitotic
entry and the proper establishment of G2/M checkpoint upon
UV irradiation. However, constitutively active JNK causes defects
in cell cycle progression. Indeed, many human tumors have been
reported to require JNK activity for their growth and survival
(Potapova et al., 2000; Antonyak et al., 2002; Tsuiki et al., 2003;
Yang et al., 2003; Lopez-Bergami et al., 2007;Alexaki et al., 2008). In
gastrointestinal cancers, a small molecule inhibitor of JNK shows
promise as a therapeutic agent, because it induces cell cycle arrest
and apoptosis (Xia et al., 2006).
Ect2
The oncogenic protein Ect2 is ubiquitinated byAPC/CCdh1 shortly
after completion of mitosis (Liot et al., 2011). Ect2 is a posi-
tive regulator of the Rho GTPase pathway that controls cell cycle
progression and cytokinesis (Bustelo et al., 2007). Many human
tumors overexpress Ect2 (Sano et al., 2006; Salhia et al., 2008;
Justilien and Fields, 2009; Justilien et al., 2011). Until now, this
overexpression was believed to be a result of gene ampliﬁcation
and transcriptional upregulation (Seguin et al., 2009; Liot et al.,
2011). But the newly discoveredAPC/CCdh1 dependent proteolysis
of Ect2 shows that impaired destruction can also be a reason for
increased Ect2 levels in tumor cells, which possibly asserts the role
of Cdh1 as a tumor suppressor protein.
Skp2
Skp2 is one of the most important substrates targeted by
APC/CCdh1 during mitotic exit. An SCF containing Skp2 targets
the essential cell cycle substrates p27Kip1, p21Cip1, and FOXO1 for
degradation (Yu et al., 1998; Tsvetkov et al., 1999; Huang et al.,
2005). Destruction of the CDK inhibitor p27Kip1 is a prerequisite
for entry into mitosis. Once cells exit mitosis, APC/CCdh1 targets
Skp2 for proteolysis in G1 (Bashir et al., 2004; Wei et al., 2004).
Skp2 functions as an oncogene because most of its ubiquitina-
tion targets are tumor suppressor proteins. Thus overexpression of
Skp2 is common in many cancers including breast cancer, prostate
cancer, pancreatic cancer, hepatocellular carcinomas, melanomas,
and malignant lymphomas (Lim et al., 2002; Yang et al., 2002;
Radke et al., 2005; Lu et al., 2009; Rose et al., 2011; Schuler et al.,
2011). Importantly, the Akt1 serine/threonine kinase phospho-
rylates Skp2 at Ser 72 promoting its cytoplasmic translocation
and impairing degradation by APC/CCdh1 (Gao et al., 2009b,c;
Lin et al., 2009). Since the Akt1 pathway is also found to be
hyperactive in cancer cells, it may contribute signiﬁcantly to over-
expression of Skp2 protein found in some cancers (Gao et al.,
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2009b,c). Opposing the Akt1 pathway is PTEN, which is fre-
quently misregulated in human brain, breast, prostate cancers, and
leukemias (Li et al., 1997;Dahia et al., 1999). Thus,PTENmisregu-
lation may contribute toAkt1 hyperactivation and increased levels
of Skp2 in tumors.
Ube2C (UbcH10)
Ube2C is an E2 enzyme that works exclusively with the APC/C
throughout the cell cycle. However, Ube2C levels peak during
mitosis and fall as cells enter G1, ﬁnally becoming a substrate for
APC/CCdh1 at the end of G1 (Rape and Kirschner, 2004; Summers
et al., 2008). When Ube2C is overexpressed in mouse embry-
onic ﬁbroblasts (MEFs), precocious cyclin B1 degradation,mitotic
slippage, and chromosome abnormalities have been observed (van
Ree et al., 2010). Importantly, elevated Ube2C levels is a com-
mon feature in a wide variety of human cancers including lung,
prostate, breast, bladder, ovarian, uterine, thyroid, esophageal,
and gastric carcinomas (Okamoto et al., 2003; Pallante et al.,
2005; Berlingieri et al., 2007; Jiang et al., 2008; van Ree et al.,
2010). Further, induced expression of high levels of Ube2C
hastens tumor formation in transgenic mice (van Ree et al.,
2010).
MODULATING APC/CCdh1 ACTIVITY IN CANCER
TARGETING APC/CCdh1SUBSTRATES
Several APC/C substrates are overexpressed in various can-
cers, making them prime targets for small molecule inhibition
(Table 2). One potential APC/C substrate that could be targeted
Table 2 | Substrates of APC/C overexpressed in cancer.
APC/C substrate Major cell cycle function(s) Role in tumorigenesis Relevant cancers Relevant reference
Nek2 Regulation of centrosome
separation and spindle
formation
Formation of multinucleated
cells with supernumerary
centrosomes
Cervical cancer, B-cell
lymphoma, pediatric
osteosarcoma, breast cancer,
leukemia, ovarian cancer
Wai et al. (2002), de Vos et al.
(2003), Hayward et al. (2004)
Cdc20 Essential APC/C coactivator in
early mitosis
Spindle checkpoint defects
and premature Securin
destruction leading to mitotic
slippage
Oral squamous cell
carcinomas, breast cancer
Yuan et al. (2006), Mondal et al.
(2007)
Plk1 Activation of MPF by
phosphorylation of Cdc25C
and Cyclin B Assembling the
mitotic spindle
Overexpression in cancer
drives cells into mitosis
Lung, ovarian, breast, colon,
prostate and pancreatic
cancers, head/neck squamous
cell carcinomas, melanomas
Wolf et al. (1997), Knecht et al.
(1999), Strebhardt et al. (2000),
Wolf et al. (2000), Macmillan
et al. (2001), Gray et al. (2004),
Weichert et al. (2004)
Aurora-A Controls centrosome
maturation and mitotic
spindle formation
Induces centrosome
ampliﬁcation and aneuploidy
by hindering APC/CCdh1
mediated destruction of
Centrin
Bladder, lung, and colon
cancers
Bischoff et al. (1998), Zhou et al.
(1998), Sen et al. (2002), Gu et al.
(2007)
HEC1 Controls kinetochore
microtubule dynamics as part
of the NDC80 complex
Chromosome
mis-segregation
Breast cancer Bieche et al. (2011)
JNK Central role in stress
response pathways Ensures
correct timing of mitotic entry
by phosphorylating Cdc25C
Supports survival of tumor
cells by controlling cell cycle
arrest and apoptosis
Brain tumors such as
glioblastoma, prostate cancer,
gastrointestinal cancers,
melanomas
Potapova et al. (2000), Antonyak
et al. (2002), Tsuiki et al. (2003),
Yang et al. (2003), Xia et al. (2006),
Lopez-Bergami et al. (2007), Alex-
aki et al. (2008)
Ect2 Positive regulator of the Rho
GTPase pathway that controls
actin cytoskeleton functions
like cytokinesis
Ensures proper cytokinesis in
tumor cells
Glioblastoma, non-small cell
lung cancer
Salhia et al. (2008), Justilien et al.
(2011)
Skp2 F-box protein that functions as
part of SCFSkp2 to degrade
Cdk inhibitors p27Kip1 and
p21Cip1
Acts as an oncogene that
destroys tumor suppressor
proteins
Breast, prostate, liver and
pancreatic cancers,
melanomas, lymphomas
Lim et al. (2002), Radke et al.
(2005), Lu et al. (2009), Rose et al.
(2011), Schuler et al. (2011)
Ube2C (UbcH10) Principal E2 enzyme the
APC/C collaborates with
Chromosome abnormalities
and mitotic slippage
Gastric carcinomas, cancers
of the lung, prostate, breast,
ovary, bladder, thyroid, uterus,
and esophagus
Okamoto et al. (2003), Pallante
et al. (2005), Berlingieri et al.
(2007), Jiang et al. (2008), van
Ree et al. (2010)
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via such a strategy is the proto-oncogene Skp2 (Fujita et al.,
2008, 2009). Downregulation of Skp2 by antisense RNA treat-
ment induces apoptosis in lung cancer cells (Yokoi et al., 2003).
Therefore, one possibility is utilizing compounds affecting Skp2
expression. For instance, treatment with EB1089 (vitamin D ana-
log) reduces Skp2 expression in treated cancer cells, thus promot-
ing increased stability of p27Kip1 protein and subsequent growth
arrest (Lin et al., 2003; Figure 3). Skp2 expression is also affected
by treatment with retinoic acid, thus altering the ability of p27Kip1
to be ubiquitinated (Nakamura et al., 2003). Furthermore, the
PPARg agonist Troglitazone reduces Skp2 mRNA levels, leading to
p27Kip1 accumulation (Koga et al., 2003).
Since the APC/C mediates Skp2 ubiquitination, enhancing
APC/C dependent degradation of Skp2 in cancer would also be
therapeutically attractive. One possible means of achieving this is
to inhibit casein kinase 1 (CK1), which controls APC/C depen-
dent degradation of Skp2 (Gao et al., 2009b,c). CK1 inhibition
induces Skp2 degradation since CK1 dependent phosphorylation
normally inhibits Skp2 nuclear translocation and interaction with
APC/CCdh1 (Gao et al., 2009b,c). An alternative strategy, however,
could be increasing the afﬁnity of Skp2 or other oncogenic sub-
strates for APC/C, thus reducing their protein levels after ubiquiti-
nation and degradation. The advent of high-throughput screens to
study APC/C-dependent degradation and protein–protein inter-
actions will facilitate identiﬁcation of small molecule agonists of
the APC/C–Skp2 interaction (Madoux et al., 2010; Zeng et al.,
2010).
Another potential APC/C cancer target is the substrate Aurora-
A, since its overexpression is known to induce centrosome ampli-
ﬁcation and is overexpressed in human cancer cells (Zhou et al.,
1998). Recently, several compounds have been found to target
Aurora-A (Figure 3). Curcumin, an active compound in turmeric
and curry that has been proven to induce tumor apoptosis and
inhibit tumor proliferation, invasion, angiogenesis, and metas-
tasis, has been shown to reduce Aurora-A mRNA expression in
human bladder cancer cells (Liu et al., 2011a). These curcumin-
induced phenomena were similar to those using Aurora-A small
interfering RNA and were attenuated by ectopic expression of
Aurora-A. Also, several cyclic peptide ligands inhibiting Aurora-A
kinase activity have beendeveloped (Shomin et al., 2011), although
future studies regarding proliferation of cancer cells still have to
be performed.
In addition to Aurora-A inhibition, there is pharmaceutical
interest in targeting Plk1 as Plk1 depletion in cancer cells dra-
matically inhibits cell proliferation and decreases viability (Liu
and Erikson, 2003; Xu et al., 2011; Yoon et al., 2011). Depletion
of Plk1 perturbs spindle assembly, which leads to activation of the
mitotic checkpoint,prolongedmitotic arrest, and eventually apop-
tosis (Liu and Erikson, 2003). Thus, given the known functions
and effects of Plk1 inhibition, coupled with its wide overexpres-
sion pattern in cancer, a naturally occurring Plk1 inhibitor with
low or no toxicity will be immensely useful in prevention as well as
treatment of cancer. Numerous Plk1 inhibitors are in development
to evaluate their potential as treatments in oncology, some of them
in preclinical and clinical phase I/II development (Schöffski, 2009;
Figure 3). It will be interesting to determine whether enhancing
APC/C mediated degradation of Plk1 yield similar therapeutic
beneﬁts as Plk1 inhibitors currently in clinical trials.
TARGETING APC/CCdh1 ACTIVITY
Several lines of evidence suggest that modulation of the APC/C
complex is a good anti-cancer therapeutic strategy. Downregula-
tionof the catalytic subunitsApc2 andApc11 leads to growth arrest
and cell death in HeLa cells (Pray et al., 2002). Also, a small mole-
cule, tosyl-l-argininemethyl ester (TAME),which binds toAPC/C
and prevents its activation by Cdc20 and Cdh1, produces mitotic
arrest (Zeng et al., 2010;Figure 3). Furthermore, expression of sev-
eral APC/C subunits is higher in tumor relative to normal tissue
(Wang et al., 2003). Collectively, these studies suggest that phar-
macological interference with APC/C activity through disruption
of protein–protein interaction is likely to have potent anti-tumor
activity (Pray et al., 2002; Huang et al., 2009).
Targeting upstream regulators of the APC/C complex control-
ling mitosis is also a promising strategy. Overexpression of APC/C
inhibitors such as Emi1 inmammalian cells impedes cell cycle pro-
gression and results in cell death (Reimann et al., 2001). HDACs
FIGURE 3 | Cancer therapeutics related to APC/CCdh1.Targeting the modulators, the APC/CCdh1 complex or its substrates could be a good anti-cancer strategy.
Some pharmacological treatments that regulate APC/C activity or substrate levels are currently in clinical trials or under development.
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might directly target APC/C to ensure proper chromosome
segregation and anti-tumor effects of HDAC inhibitors could be
attributed to this deregulation (Kimata et al., 2008). There are
emerging HDAC inhibitors that have been clinically validated as
therapeutic agents in cancer patients with hematologic malignan-
cies. Two HDAC inhibitors, vorinostat (pan-HDAC inhibitor) and
depsipeptide (HDAC1 and II inhibitor) have been approved by the
FDAand are under further clinical investigation (Figure 3).HDAC
inhibitors are well tolerated and clinically effective against hema-
tologic cancers (Duvic and Vu, 2007; Luu et al., 2008; Modesitt
et al., 2008).
CONCLUDING REMARKS
The APC/C is a unique ubiquitin ligase since it possesses a dis-
tinct structure and interacts with speciﬁc E2 enzymes required for
mediating substrate ubiquitination. Further, APC/CCdc20 activity
is essential in vitro and in vivo, suggesting that no other ubiquitin
ligase can substitute forAPC/C’s role duringmitosis (Li et al., 2007;
Manchado et al., 2010). Similarly, APC/CCdh1 activity is required
for cell cycle traverse, differentiation, placental formation, and for
inhibiting tumorigenesis (Garcia-Higuera et al., 2008; Li et al.,
2008). These exciting studies suggest that APC/C plays a large role
in normal cell proliferation, which may be misregulated during
cancer. Consistent with this notion are new studies linking APC/C
substrates and regulators to tumor formation. Thus, it may be
attractive to modulate APC/C substrate or regulator interaction
pharmacologically to ablate tumor growth, which would have the
advantage that speciﬁc interactions relevant to a cancer type can
be uniquely targeted.
ACKNOWLEDGMENTS
We thank Ms. Satu Hyvarinen for helpful discussions and crit-
ical reading of the manuscript. We thank all members of the
Wahlestedt laboratory and the Center for Therapeutic Innovation
for helpful discussions. We apologize if we have omitted stud-
ies linking APC/C modulators and substrates to differentiation or
tumorigenesis due to space constraints. This work was supported
by R01NS067289-03.
REFERENCES
Abrieu, A., Brassac, T., Galas, S., Fisher,
D., Labbe, J. C., and Doree, M.
(1998). The polo-like kinase Plx1 is
a component of the MPF ampliﬁca-
tion loop at the G2/M-phase transi-
tion of the cell cycle in Xenopus eggs.
J. Cell Sci. 111, 1751–1757.
Acquaviva, C., and Pines, J. (2006).
The anaphase-promoting com-
plex/cyclosome: APC/C. J. Cell Sci.
119, 2401–2404.
Albanese, C., Johnson, J., Watanabe, G.,
Eklund, N., Vu, D., Arnold, A., and
Pestell, R. G. (1995). Transforming
p21ras mutants and c-ets-2 activate
the cyclin D1 promoter through dis-
tinguishable regions. J. Biol. Chem.
270, 23589–23597.
Alexaki, V. I., Javelaud, D., and Mauviel,
A. (2008). JNK supports survival in
melanoma cells by controlling cell
cycle arrest and apoptosis. Pigment
Cell Melanoma Res. 21, 429–438.
Almeida, A., Bolanos, J. P., and Moreno,
S. (2005). Cdh1/Hct1-APC is essen-
tial for the survival of postmitotic
neurons. J. Neurosci. 25, 8115–8121.
Antonyak, M. A., Kenyon, L. C., God-
win, A. K., James, D. C., Emlet, D.
R.,Okamoto, I.,Tnani,M.,Holgado-
Madruga, M., Moscatello, D. K., and
Wong, A. J. (2002). Elevated JNK
activation contributes to the patho-
genesis of human brain tumors.
Oncogene 21, 5038–5046.
Araki, M., Wharton, R. P., Tang, Z.,
Yu, H., and Asano, M. (2003).
Degradation of origin recogni-
tion complex large subunit by
the anaphase-promoting complex
in drosophila. EMBO J. 22,
6115–6126.
Baghdoyan, S., Lamartine, J., Cas-
tel, D., Pitaval, A., Roupioz, Y.,
Franco, N., Duarte, M., Martin,
M. T., and Gidrol, X. (2005). Id2
reverses cell cycle arrest induced
by {gamma}-irradiation in human
HaCaT keratinocytes. J. Biol. Chem.
280, 15836–15841.
Barford, D. (2011). Structure, function
andmechanismof the anaphase pro-
moting complex (APC/C). Q. Rev.
Biophys. 44, 153–190.
Bar-On, O., Shapira, M., Skorecki,
K., Hershko, A., and Hershko, D.
D. (2010). Regulation of APC/C
(Cdh1) ubiquitin ligase in differen-
tiation of human embryonic stem
cells. Cell Cycle 9, 1986–1989.
Bashir, T., Dorrello, N. V., Amador, V.,
Guardavaccaro, D., and Pagano, M.
(2004). Control of the SCF(Skp2-
Cks1) ubiquitin ligase by the
APC/C(Cdh1) ubiquitin ligase.
Nature 428, 190–193.
Bassermann, F., Frescas, D., Guardavac-
caro, D., Busino, L., Peschiaroli,
A., and Pagano, M. (2008). The
Cdc14B-Cdh1-Plk1 axis controls the
G2 DNA-damage-response check-
point. Cell 134, 256–267.
Beheshti, B., Park, P. C., Sweet, J. M.,
Trachtenberg, J., Jewett, M. A., and
Squire, J. A. (2001). Evidence of
chromosomal instability in prostate
cancer determined by spectral kary-
otyping (SKY) and interphase ﬁsh
analysis. Neoplasia 3, 62–69.
Bell, E. L., Emerling, B. M., Ricoult, S.
J., and Guarente, L. (2011). SirT3
suppresses hypoxia inducible factor
1alpha and tumor growth by inhibit-
ing mitochondrial ROS production.
Oncogene 30, 2986–2996.
Benmaamar, R., and Pagano,M. (2005).
Involvement of the SCF complex
in the control of Cdh1 degra-
dation in S-phase. Cell Cycle 4,
1230–1232.
Berlingieri,M. T.,Pallante,P.,Guida,M.,
Nappi, C., Masciullo, V., Scambia,
G., Ferraro, A., Leone, V., Sboner, A.,
Barbareschi,M., Ferro,A., Troncone,
G., and Fusco, A. (2007). UbcH10
expression may be a useful tool in
theprognosis of ovarian carcinomas.
Oncogene 26, 2136–2140.
Bieche, I., Vacher, S., Lallemand,
F., Tozlu-Kara, S., Bennani, H.,
Beuzelin, M., Driouch, K., Rouleau,
E., Lerebours, F., Ripoche, H.,
Cizeron-Clairac, G., Spyratos, F.,
and Lidereau, R. (2011). Expression
analysis of mitotic spindle check-
point genes in breast carcinoma:
role of NDC80/HEC1 in early breast
tumorigenicity, and a two-gene sig-
nature for aneuploidy. Mol. Cancer
10, 23.
Binné, U. K., Classon, M. K., Dick, F.
A., Wei, W., Rape, M., Kaelin, W.
G. Jr, Näär, A. M., and Dyson, N. J.
(2007). Retinoblastoma protein and
anaphase-promoting complex phys-
ically interact and functionally coop-
erate during cell-cycle exit. Nat. Cell
Biol. 9, 225–232.
Bischoff, J. R., Anderson, L., Zhu,
Y., Mossie, K., Ng, L., Souza, B.,
Schryver, B., Flanagan, P., Clairvoy-
ant, F., Ginther, C., Chan, C. S.,
Novotny, M., Slamon, D. J., and
Plowman, G. D. (1998). A homo-
logue of Drosophila aurora kinase is
oncogenic and ampliﬁed in human
colorectal cancers. EMBO J. 17,
3052–3065.
Blanco-Aparicio, C., Renner, O., Leal, J.
F., and Carnero, A. (2007). PTEN,
more than the AKT pathway. Car-
cinogenesis 28, 1379–1386.
Bolden, J. E., Peart, M. J., and John-
stone, R. W. (2006). Anticancer
activities of histone deacetylase
inhibitors. Nat. Rev. Drug Discov. 5,
769–784.
Bornstein, G., Bloom, J., Sitry-Shevah,
D., Nakayama, K., Pagano, M., and
Hershko,A. (2003). Role of the SCF-
Skp2 ubiquitin ligase in the degra-
dation of p21Cip1 in S phase. J. Biol.
Chem. 278, 25752–25757.
Brandeis, M., and Hunt, T. (1996).
The proteolysis of mitotic cyclins
in mammalian cells persists from
the end of mitosis until the
onset of S phase. EMBO J. 15,
5280–5289.
Brown, N. R., Noble, M. E., Lawrie,
A. M., Morris, M. C., Tunnah, P.,
Divita, G., Johnson, L. N., and Endi-
cott, J. A. (1999). Effects of phos-
phorylation of threonine 160 on
cyclin-dependent kinase 2 structure
and activity. J. Biol. Chem. 274,
8746–8756.
Burger, M. J., Tebay, M. A., Keith, P.
A., Samaratunga, H. M., Clements,
J., Lavin, M. F., and Gardiner,
R. A. (2002). Expression analy-
sis of delta-catenin and prostate-
speciﬁc membrane antigen: their
potential as diagnostic markers for
prostate cancer. Int. J. Cancer 100,
228–237.
Bustelo, X. R., Sauzeau, V., and Beren-
jeno, I.M. (2007). GTP-binding pro-
teins of the Rho/Rac family: regula-
tion, effectors and functions in vivo.
Bioessays 29, 356–370.
www.frontiersin.org January 2012 | Volume 1 | Article 60 | 13
Penas et al. APC/C role in cancer
Cairns, P., Okami, K., Halachmi, S.,
Halachmi, N., Esteller, M., Herman,
J. G., Jen, J., Isaacs,W. B., Bova, G. S.,
and Sidransky, D. (1997). Frequent
inactivation of PTEN/MMAC1 in
primary prostate cancer. Cancer Res.
57, 4997–5000.
Carrano, A. C., Eytan, E., Hershko,
A., and Pagano, M. (1999). SKP2
is required for ubiquitin-mediated
degradation of the CDK inhibitor
p27. Nat. Cell Biol. 1, 193–199.
Carruthers, S., Mason, J., and Papalop-
ulu, N. (2003). Depletion of the
cell-cycle inhibitor p27(Xic1)
impairs neuronal differentiation
and increases the number of
ElrC(+) progenitor cells in Xenopus
tropicalis. Mech. Dev. 120, 607–616.
Chabes, A. L., Pﬂeger, C. M., Kirschner,
M. W., and Thelander, L. (2003).
Mouse ribonucleotide reductase
R2 protein: a new target for
anaphase-promoting complex-
Cdh1-mediated proteolysis.
Proc. Natl. Acad. Sci. U.S.A.
100, 3925–3929.
Chalhoub, N., and Baker, S. J. (2009).
PTEN and the PI3-kinase pathway
in cancer. Annu. Rev. Pathol. 4,
127–150.
Chang, S. S., Reuter, V. E., Heston, W.
D., Bander, N. H., Grauer, L. S.,
and Gaudin, P. B. (1999). Five dif-
ferent anti-prostate-speciﬁc mem-
brane antigen (PSMA) antibodies
conﬁrm PSMA expression in tumor-
associated neovasculature. Cancer
Res. 59, 3192–3198.
Chang, S. S., Reuter, V. E., Heston, W.
D., and Gaudin, P. B. (2001). Com-
parison of anti-prostate-speciﬁc
membrane antigen antibodies and
other immunomarkers in metastatic
prostate carcinoma. Urology 57,
1179–1183.
Chaudhary, J., Sadler-Riggleman, I.,
Ague, J. M., and Skinner, M.
K. (2005). The helix-loop-helix
inhibitor of differentiation (ID) pro-
teins induce post-mitotic terminally
differentiated sertoli cells to re-enter
the cell cycle and proliferate. Biol.
Reprod. 72, 1205–1217.
Chen, H. Z., Tsai, S. Y., and Leone,
G. (2009). Emerging roles of
E2Fs in cancer: an exit from cell
cycle control. Nat. Rev. Cancer 9,
785–797.
Chen, Y., Riley, D. J., Chen, P. L.,
and Lee, W. H. (1997). HEC, a
novel nuclear protein rich in leucine
heptad repeats speciﬁcally involved
in mitosis. Mol. Cell. Biol. 17,
6049–6056.
Chen, Y., Riley, D. J., Zheng, L., Chen,
P. L., and Lee, W. H. (2002).
Phosphorylation of the mitotic
regulator protein Hec1 by Nek2
kinase is essential for faithful chro-
mosome segregation. J. Biol. Chem.
277, 49408–49416.
Classon,M., and Harlow, E. (2002). The
retinoblastoma tumour suppressor
in development and cancer.Nat. Rev.
Cancer 2, 910–917.
Cobrinik, D. (2005). Pocket proteins
and cell cycle control. Oncogene 24,
2796–2809.
Cochrane, S. W., Zhao, Y., Wel-
ner, R. S., and Sun, X. H.
(2009). Balance between id and E
proteins regulates myeloid-versus-
lymphoid lineage decisions. Blood
113, 1016–1026.
Contestabile, A., Fila, T., Bartesaghi, R.,
and Ciani, E. (2009). Cell cycle elon-
gation impairs proliferation of cere-
bellar granule cell precursors in the
Ts65Dn mouse, an animal model for
down syndrome. Brain Pathol. 19,
224–237.
Cotto-Rios, X. M., Jones, M. J., Busino,
L., Pagano, M., and Huang, T.
T. (2011). APC/CCdh1-dependent
proteolysis of USP1 regulates the
response to UV-mediated DNA
damage. J. Cell Biol. 194, 177–186.
Cuende, J., Moreno, S., Bolanos, J. P.,
and Almeida, A. (2008). Retinoic
acid downregulates Rae1 leading to
APC(Cdh1) activation and neurob-
lastoma SH-SY5Y differentiation.
Oncogene 27, 3339–3344.
Dahia, P. L., Aguiar, R. C., Alberta, J.,
Kum, J. B., Caron, S., Sill, H., Marsh,
D. J., Ritz, J., Freedman, A., Stiles,
C., and Eng, C. (1999). PTEN is
inversely correlated with the cell sur-
vival factor Akt/PKB and is inac-
tivated via multiple mechanismsin
haematological malignancies. Hum.
Mol. Genet. 8, 185–193.
Daley, G. Q. (2008). Common themes
of dedifferentiation in somatic cell
reprogramming and cancer. Cold
Spring Harb. Symp. Quant. Biol. 73,
171–174.
de Vos, S., Hofmann, W. K., Gro-
gan, T. M., Krug, U., Schrage, M.,
Miller, T. P., Braun, J. G., Wachs-
man, W., Koefﬂer, H. P., and Said,
J. W. (2003). Gene expression pro-
ﬁle of serial samples of transformed
B-cell lymphomas. Lab. Invest. 83,
271–285.
Deng, C. X. (2009). SIRT1, is it a tumor
promoter or tumor suppressor? Int.
J. Biol. Sci. 5, 147–152.
Denning, G., Jean-Joseph, B., Prince,
C., Durden, D. L., and Vogt, P. K.
(2007).A shortN-terminal sequence
of PTEN controls cytoplasmic local-
ization and is required for suppres-
sion of cell growth. Oncogene 26,
3930–3940.
Depamphilis,M. L. (2011). Spotlight on
geminin. Breast Cancer Res. 13, 109.
Di Cristofano, A., Pesce, B., Cordon-
Cardo, C., and Pandolﬁ, P. P. (1998).
Pten is essential for embryonic
development and tumour suppres-
sion. Nat. Genet. 19, 348–355.
Difﬂey, J. F. (2004). Regulation of early
events in chromosome replication.
Curr. Biol. 14, R778–R786.
Dube, P.,Herzog, F., Gieffers, C., Sander,
B., Riedel, D., Muller, S. A., Engel,
A., Peters, J. M., and Stark, H.
(2005). Localization of the coactiva-
torCdh1 and the cullin subunitApc2
in a cryo-electronmicroscopymodel
of vertebrate APC/C. Mol. Cell 20,
867–879.
Durand, B., Fero, M. L., Roberts, J. M.,
and Raff, M. C. (1998). p27Kip1
alters the response of cells to mito-
gen and is part of a cell-intrinsic
timer that arrests the cell cycle and
initiates differentiation.Curr. Biol. 8,
431–440.
Duvic, M., and Vu, J. (2007). Vorino-
stat: a new oral histone deacetylase
inhibitor approved for cutaneous T-
cell lymphoma. Expert Opin. Inves-
tig. Drugs 16, 1111–1120.
Eckerdt, F., Yuan, J., and Strebhardt, K.
(2005). Polo-like kinases and onco-
genesis. Oncogene 24, 267–276.
Eckerle, I.,Muth,D., Batzler, J.,Henrich,
K. O., Lutz, W., Fischer, M., Witt,
O., Schwab, M., and Westermann,
F. (2009). Regulation of BIRC5 and
its isoform BIRC5-2B in neuroblas-
toma. Cancer Lett. 285, 99–107.
Engelbert, D., Schnerch, D., Baum-
garten, A., and Wasch, R. (2008).
The ubiquitin ligase APC(Cdh1)
is required to maintain genome
integrity in primary human cells.
Oncogene 27, 907–917.
Fang, G., Yu, H., and Kirschne, M. W.
(1998). Direct binding of CDC20
protein family members activates
the anaphase-promoting complex in
mitosis andG1.Mol. Cell 2,163–171.
Feilotter,H. E.,Nagai,M.A.,Boag,A.H.,
Eng, C., and Mulligan, L. M. (1998).
Analysis of PTEN and the 10q23
region in primary prostate carcino-
mas. Oncogene 16, 1743–1748.
Fero,M. L.,Rivkin,M.,Tasch,M.,Porter,
P., Carow, C. E., Firpo, E., Polyak,
K., Tsai, L. H., Broudy, V., Perl-
mutter, R. M., Kaushansky, K., and
Roberts, J. M. (1996). A syndrome
of multiorgan hyperplasia with fea-
tures of gigantism, tumorigenesis,
and female sterility in p27(Kip1)-
deﬁcient mice. Cell 85, 733–744.
Fu, Z., Schroeder, M. J., Shabanowitz,
J., Kaldis, P., Togawa, K., Rustgi,
A. K., Hunt, D. F., and Sturgill,
T. W. (2005). Activation of a
nuclear Cdc2-related kinase within
a mitogen-activated protein kinase-
like TDY motif by autophosphory-
lation and cyclin-dependent protein
kinase-activating kinase. Mol. Cell.
Biol. 25, 6047–6064.
Fujita, T., Liu, W., Doihara, H., and
Wan, Y. (2008). Regulation of Skp2-
p27 axis by the Cdh1/anaphase-
promoting complex pathway in col-
orectal tumorigenesis. Am. J. Pathol.
173, 217–228.
Fujita, T., Liu, W., Doihara, H., and
Wan, Y. (2009). An in vivo study of
Cdh1/APC in breast cancer forma-
tion. Int. J. Cancer 125, 826–836.
Ganoth, D., Bornstein, G., Ko, T. K.,
Larsen, B., Tyers, M., Pagano, M.,
and Hershko, A. (2001). The cell-
cycle regulatory protein Cks1 is
required for SCF(Skp2)-mediated
ubiquitinylation of p27. Nat. Cell
Biol. 3, 321–324.
Gao, D., Inuzuka, H., Korenjak,
M., Tseng, A., Wu, T., Wan, L.,
and Kirschner M, Dyson N, Wei
W. (2009a). Cdh1 regulates cell
cycle through modulating the
claspin/Chk1 and the Rb/E2F1
pathways. Mol. Biol. Cell 20,
3305–3316.
Gao, D., Inuzuka, H., Tseng, A., Chin,
R. Y., Toker, A., and Wei, W.
(2009b). Phosphorylation by Akt1
promotes cytoplasmic localization
of Skp2 and impairs APCCdh1-
mediated Skp2 destruction.Nat. Cell
Biol. 11, 397–408.
Gao,D., Inuzuka,H., Tseng,A., andWei,
W. (2009c). Akt ﬁnds its new path to
regulate cell cycle through modulat-
ing Skp2 activity and its destruction
by APC/Cdh1. Cell Div. 4, 11.
Garcia-Higuera, I., Manchado, E.,
Dubus, P., Canamero, M., Mendez,
J., Moreno, S., and Malumbres,
M. (2008). Genomic stability and
tumour suppression by the APC/C
cofactor Cdh1. Nat. Cell Biol. 10,
802–811.
Garnett, M. J., Mansfeld, J., Godwin,
C., Matsusaka, T., Wu, J., Russell, P.,
Pines, J., and Venkitaraman, A. R.
(2009). UBE2S elongates ubiquitin
chains on APC/C substrates to pro-
mote mitotic exit. Nat. Cell Biol. 11,
1363–1369.
Gayraud-Morel, B., Chretien, F., Fla-
mant, P., Gomes, D., Zammit, P. S.,
and Tajbakhsh, S. (2007). A role for
the myogenic determination gene
Myf5 in adult regenerative myoge-
nesis. Dev. Biol. 312, 13–28.
Ge, S., Skaar, J. R., and Pagano,
M. (2009). APC/C- and Mad2-
mediated degradation of Cdc20 dur-
ing spindle checkpoint activation.
Cell Cycle 8, 167–171.
Frontiers in Oncology | Molecular and Cellular Oncology January 2012 | Volume 1 | Article 60 | 14
Penas et al. APC/C role in cancer
Georgescu, M. M., Kirsch, K. H.,
Kaloudis, P., Yang, H., Pavletich, N.
P., and Hanafusa, H. (2000). Stabi-
lization and productive positioning
roles of the C2 domain of PTEN
tumor suppressor. Cancer Res. 60,
7033–7038.
Ghosh, A., and Heston, W. D. (2004).
Tumor target prostate speciﬁc mem-
brane antigen (PSMA) and its reg-
ulation in prostate cancer. J. Cell.
Biochem. 91, 528–539.
Gieffers, C., Dube, P., Harris, J. R.,
Stark, H., and Peters, J. M. (2001).
Three-dimensional structure of the
anaphase-promoting complex. Mol.
Cell 7, 907–913.
Gieffers, C., Peters, B. H., Kramer, E.
R., Dotti, C. G., and Peters, J. M.
(1999). Expression of the CDH1-
associated form of the anaphase-
promoting complex in postmitotic
neurons. Proc. Natl. Acad. Sci. U.S.A.
96, 11317–11322.
Gildea, J. J., Herlevsen, M., Harding, M.
A., Gulding, K. M., Moskaluk, C. A.,
Frierson, H. F., and Theodorescu, D.
(2004). PTEN can inhibit in vitro
organotypic and in vivo orthotopic
invasion of human bladder cancer
cells even in the absence of its lipid
phosphatase activity. Oncogene 23,
6788–6797.
Glaser, K. B., Li, J., Staver, M. J., Wei,
R. Q., Albert, D. H., and Davidsen,
S. K. (2003). Role of class I and
class II histone deacetylases in car-
cinoma cells using siRNA. Biochem.
Biophys. Res. Commun. 310,
529–536.
Glotzer, M., Murray, A. W., and
Kirschner, M. W. (1991). Cyclin is
degraded by the ubiquitin pathway.
Nature 349, 132–138.
Gmachl, M., Gieffers, C., Podtelejnikov,
A. V., Mann, M., and Peters, J. M.
(2000). The RING-H2 ﬁnger protein
APC11 and the E2 enzyme UBC4
are sufﬁcient to ubiquitinate sub-
strates of the anaphase-promoting
complex.Proc. Natl. Acad. Sci. U.S.A.
97, 8973–8978.
Gray, I. C., Stewart, L. M., Phillips, S.
M.,Hamilton, J. A., Gray,N. E.,Wat-
son, G. J., Spurr, N. K., and Snary,
D. (1998). Mutation and expres-
sion analysis of the putative prostate
tumour-suppressor gene PTEN. Br.
J. Cancer 78, 1296–1300.
Gray, P. J., Bearss, D. J., Han, H., Nagle,
R., Tsao, M. S., Dean, N., and Von
Hoff, D. D. (2004). Identiﬁcation of
human polo-like kinase 1 as a poten-
tial therapeutic target in pancreatic
cancer.Mol.CancerTher. 3,641–646.
Gu, J.,Gong,Y.,Huang,M., Lu,C., Spitz,
M. R., and Wu, X. (2007). Polymor-
phisms of STK15 (aurora-A) gene
and lung cancer risk in Caucasians.
Carcinogenesis 28, 350–355.
Guardavaccaro,D.,Kudo,Y., Boulaire, J.,
Barchi, M., Busino, L., Donzelli, M.,
Margottin-Goguet, F., Jackson, P. K.,
Yamasaki, L., and Pagano,M. (2003).
Control of meiotic and mitotic pro-
gression by the F box protein beta-
Trcp1 in vivo. Dev. Cell 4, 799–812.
Gütgemann, I., Lehman, N. L., Jack-
son, P. K., and Longacre, T.
A. (2008). Emi1 protein accu-
mulation implicates misregulation
of the anaphase promoting com-
plex/cyclosome pathway in ovarian
clear cell carcinoma.Mod. Pathol. 21,
445–454.
Gutierrez,G. J.,Tsuji,T.,Chen,M., Jiang,
W., and Ronai, Z. A. (2010a). Inter-
play between Cdh1 and JNK activity
during the cell cycle. Nat. Cell Biol.
12, 686–695.
Gutierrez, G. J., Tsuji, T., Cross, J.
V., Davis, R. J., Templeton, D. J.,
Jiang, W., and Ronai, Z. A. (2010b).
JNK-mediated phosphorylation of
Cdc25C regulates cell cycle entry and
G(2)/M DNA damage checkpoint. J.
Biol. Chem. 285, 14217–14228.
Hansen, D. V., Loktev, A. V., Ban, K.
H., and Jackson, P. K. (2004). Plk1
regulates activation of the anaphase
promoting complex by phosphory-
lating and triggering SCFbetaTrCP-
dependent destruction of the APC
inhibitor Emi1. Mol. Biol. Cell 15,
5623–5634.
Harmey, D., Smith, A., Simanski, S.,
Moussa, C. Z., and Ayad, N. G.
(2009). The anaphase promoting
complex induces substrate degrada-
tionduringneuronal differentiation.
J. Biol. Chem. 284, 4317–4323.
Havrda,M.C.,Harris,B. T.,Mantani,A.,
Ward, N. M., Paolella, B. R., Cuzon,
V. C., Yeh, H. H., and Israel, M. A.
(2008). Id2 is required for speciﬁca-
tion of dopaminergic neurons dur-
ing adult olfactory neurogenesis. J.
Neurosci. 28, 14074–14086.
Hayes, M. J., Kimata, Y., Wattam, S. L.,
Lindon, C., Mao, G., Yamano, H.,
and Fry, A. M. (2006). Early mitotic
degradation of Nek2A depends
on Cdc20-independent interaction
with the APC/C. Nat. Cell Biol. 8,
607–614.
Hayward, D. G., Clarke, R. B., Faragher,
A. J., Pillai, M. R., Hagan, I. M.,
and Fry, A. M. (2004). The cen-
trosomal kinase Nek2 displays ele-
vated levels of protein expression in
human breast cancer. Cancer Res. 64,
7370–7376.
Hollander, M. C., Blumenthal, G. M.,
and Dennis, P. A. (2011). PTEN
loss in the continuum of common
cancers, rare syndromes and mouse
models. Nat. Rev. Cancer 11, 289–
301.
Hsu, J. Y., Reimann, J. D., Sorensen,
C. S., Lukas, J., and Jackson, P. K.
(2002). E2F-dependent accumula-
tionof hEmi1 regulates S phase entry
by inhibiting APC(Cdh1). Nat. Cell
Biol. 4, 358–366.
Huang, H., Regan, K. M., Wang, F.,
Wang, D., Smith, D. I., van Deursen,
J. M., and Tindall, D. J. (2005). Skp2
inhibits FOXO1 in tumor suppres-
sion through ubiquitin-mediated
degradation. Proc. Natl. Acad. Sci.
U.S.A. 102, 1649–1654.
Huang, H. C., Shi, J., Orth, J. D., and
Mitchison,T. J. (2009). Evidence that
mitotic exit is a better cancer thera-
peutic target than spindle assembly.
Cancer Cell 16, 347–358.
Hutchins, J. R., Toyoda, Y., Hegemann,
B., Poser, I., Heriche, J. K., Sykora,
M. M., Augsburg, M., Hudecz, O.,
Buschhorn, B. A., Bulkescher, J.,
Conrad, C., Comartin, D., Schleiffer,
A., Sarov,M., Pozniakovsky,A., Slab-
icki, M. M., Schloissnig, S., Stein-
macher, I., Leuschner, M., Ssykor, A.,
Lawo, S., Pelletier, L., Stark, H., Nas-
myth, K., Ellenberg, J., Durbin, R.,
Buchholz, F., Mechtler, K., Hyman,
A. A., and Peters, J. M. (2010).
Systematic analysis of human pro-
tein complexes identiﬁes chromo-
some segregation proteins. Science
328, 593–599.
Inoue, T., Hiratsuka, M., Osaki, M.,
Yamada, H., Kishimoto, I., Yam-
aguchi, S., Nakano, S., Katoh, M.,
Ito, H., and Oshimura, M. (2007).
SIRT2, a tubulin deacetylase, acts
to block the entry to chromosome
condensation in response to mitotic
stress. Oncogene 26, 945–957.
Irniger, S., and Nasmyth, K. (1997).
The anaphase-promoting complex is
required in G1 arrested yeast cells
to inhibit B-type cyclin accumula-
tion and to prevent uncontrolled
entry into S-phase. J. Cell Sci. 110,
1523–1531.
Jackson, P. K. (2006). Developmental
neurobiology: a destructive switch
for neurons. Nature 442, 365–366.
Ji, M., Li, H., Suh, H. C., Klarmann,
K. D., Yokota, Y., and Keller, J.
R. (2008). Id2 intrinsically regu-
lates lymphoid and erythroid devel-
opment via interaction with dif-
ferent target proteins. Blood 112,
1068–1077.
Ji, P., Jiang, H., Rekhtman, K., Bloom, J.,
Ichetovkin,M.,Pagano,M., andZhu,
L. (2004). An Rb-Skp2-p27 pathway
mediates acute cell cycle inhibition
by Rb and is retained in a partial-
penetrance Rb mutant. Mol. Cell 16,
47–58.
Jiang, L., Huang, C. G., Lu, Y. C.,
Luo, C., Hu, G. H., Liu, H. M.,
Chen, J. X., and Han, H. X. (2008).
Expression of ubiquitin-conjugating
enzyme E2C/UbcH10 in astrocytic
tumors. Brain Res. 1201, 161–166.
Johnstone,R.W., and Licht, J. D. (2003).
Histone deacetylase inhibitors in
cancer therapy: is transcription the
primary target?Cancer Cell 4, 13–18.
Jung, S., Park, R. H., Kim, S., Jeon, Y.
J., Ham, D. S., Jung, M. Y., Kim, S.
S., Lee, Y. D., Park, C. H., and Suh-
Kim, H. (2010). Id proteins facili-
tate self-renewal and proliferation of
neural stem cells. Stem Cells Dev. 19,
831–841.
Justilien, V., and Fields, A. P. (2009).
Ect2 links the PKCiota-Par6alpha
complex to Rac1 activation and cel-
lular transformation. Oncogene 28,
3597–3607.
Justilien, V., Jameison, L., Der, C. J.,
Rossman, K. L., and Fields, A. P.
(2011). Oncogenic activity of Ect2
is regulated through protein kinase
C iota-mediated phosphorylation. J.
Biol. Chem. 286, 8149–8157.
Kawakami, M., and Nakayama, J.
(1997). Enhanced expression of
prostate-speciﬁc membrane antigen
gene in prostate cancer as revealed
by in situ hybridization. Cancer Res.
57, 2321–2324.
Kawamoto,H.,Wada,H.,andKatsura,Y.
(2010). A revised scheme for devel-
opmental pathways of hematopoi-
etic cells: the myeloid-based model.
Int. Immunol. 22, 65–70.
Ke, P. Y., Kuo, Y. Y., Hu, C. M., and
Chang,Z. F. (2005).Control of dTTP
pool size by anaphase promoting
complex/cyclosome is essential for
the maintenance of genetic stability.
Genes Dev. 19, 1920–1933.
Kim, H. S., Vassilopoulos, A., Wang, R.
H., Lahusen, T., Xiao, Z., Xu, X.,
Li, C., Veenstra, T. D., Li, B., Yu,
H., Ji, J., Wang, X. W., Park, S. H.,
Cha, Y. I., Gius, D., and Deng, C.
X. (2011). SIRT2 maintains genome
integrity and suppresses tumorigen-
esis through regulatingAPC/C activ-
ity. Cancer Cell 20, 487–499.
Kim, S., and Yu, H. (2011). Mutual reg-
ulation between the spindle check-
point and APC/C. Semin. Cell Dev.
Biol. 22, 551–558.
Kimata, Y., Matsuyama, A., Nagao, K.,
Furuya, K., Obuse, C., Yoshida, M.,
and Yanagida, M. (2008). Diminish-
ing HDACs by drugs or mutations
promotes normal or abnormal sis-
ter chromatid separation by affect-
ing APC/C and adherin. J. Cell Sci.
121, 1107–1118.
Kitajima, S., Kudo, Y., Ogawa, I., Tat-
suka, M., Kawai, H., Pagano, M., and
www.frontiersin.org January 2012 | Volume 1 | Article 60 | 15
Penas et al. APC/C role in cancer
Takata, T. (2007). Constitutive phos-
phorylation of aurora-a on ser51
induces its stabilization and conse-
quent overexpression in cancer.PLoS
ONE 2, e944. doi:10.1371/jour-
nal.pone.0000944
Knecht, R., Elez, R., Oechler, M., Sol-
bach, C., von Ilberg, C., and Streb-
hardt, K. (1999). Prognostic signif-
icance of polo-like kinase (PLK)
expression in squamous cell carci-
nomas of the head and neck. Cancer
Res. 59, 2794–2797.
Koga, H., Harada, M., Ohtsubo,
M., Shishido, S., Kumemura, H.,
Hanada, S., Taniguchi, E.,Yamashita,
K.,Kumashiro,R.,Ueno,T., andSata,
M. (2003). Troglitazone induces
p27Kip1-associated cell-cycle arrest
through down-regulating Skp2 in
human hepatoma cells. Hepatology
37, 1086–1096.
Kops, G. J., Van Der Voet, M., Manak,
M. S., Van Osch, M. H., Naini,
S. M., Brear, A., Mcleod, I. X.,
Hentschel, D. M., Yates, J. R. III,
Van Den Heuvel, S., and Shah, J.
V. (2010). APC16 is a conserved
subunit of the anaphase-promoting
complex/cyclosome. J. Cell Sci. 123,
1623–1633.
Kotani, S., Tugendreich, S., Fujii, M.,
Jorgensen, P. M., Watanabe, N.,
Hoog, C., Hieter, P., and Todokoro,
K. (1998). PKA and MPF-activated
polo-like kinase regulate anaphase-
promoting complex activity and
mitosis progression. Mol. Cell 1,
371–380.
Koul, D., Jasser, S. A., Lu, Y., Davies,
M. A., Shen, R., Shi, Y., Mills, G.
B., and Yung, W. K. A. (2002a).
Motif analysis of the tumor suppres-
sor gene MMAC/PTEN identiﬁes
tyrosines critical for tumor suppres-
sion and lipid phosphatase activity.
Oncogene 21, 2357–2364.
Koul, D., Shen, R., Garyali, A., Ke,
L. D., Liu, T. J., and Yung, W.
K. (2002b). MMAC/PTEN tumor
suppressor gene regulates vascular
endothelial growth factor-mediated
angiogenesis in prostate cancer. Int.
J. Oncol. 21, 469–475.
Kouzarides, T. (1999). Histone acety-
lases and deacetylases in cell prolif-
eration. Curr. Opin. Genet. Dev. 9,
40–48.
Kowanetz, M., Valcourt, U., Bergstrom,
R., Heldin, C. H., and Moustakas,
A. (2004). Id2 and Id3 deﬁne the
potency of cell proliferation and dif-
ferentiation responses to transform-
ing growth factor beta and bone
morphogenetic protein. Mol. Cell.
Biol. 24, 4241–4254.
Kuo, M. H., and Allis, C. D. (1998).
Roles of histone acetyltransferases
and deacetylases in gene regulation.
Bioessays 20, 615–626.
Kwon, C. H., Zhao, D., Chen, J., Alcan-
tara, S., Li, Y., Burns, D. K., Mason,
R. P., Lee, E. Y., Wu, H., and Parada,
L. F. (2008). Pten haploinsufﬁciency
accelerates formation of high-grade
astrocytomas. Cancer Res. 68, 3286–
3294.
Lagger, G., O’Carroll, D., Rembold,
M., Khier, H., Tischler, J., Weitzer,
G., Schuettengruber, B., Hauser, C.,
Brunmeir, R., Jenuwein, T., and
Seiser, C. (2002). Essential function
of histone deacetylase 1 in prolif-
eration control and CDK inhibitor
repression. EMBO J. 21, 2672–2681.
Lane, H. A., and Nigg, E. A. (1996).
Antibody microinjection reveals an
essential role for human polo-like
kinase 1 (Plk1) in the functional
maturation of mitotic centrosomes.
J. Cell Biol. 135, 1701–1713.
Lasorella, A., Boldrini, R., Dominici, C.,
Donfrancesco,A.,Yokota,Y., Inserra,
A., and Iavarone, A. (2002). Id2 is
critical for cellular proliferation and
is the oncogenic effector of N-myc in
human neuroblastoma. Cancer Res.
62, 301–306.
Lasorella, A., and Iavarone, A. (2006).
The protein ENH is a cytoplasmic
sequestration factor for Id2 in nor-
mal and tumor cells from the ner-
vous system. Proc. Natl. Acad. Sci.
U.S.A. 103, 4976–4981.
Lee, J. O., Yang, H., Georgescu, M. M.,
Di Cristofano, A., Maehama, T., Shi,
Y., Dixon, J. E., Pandolﬁ, P., and
Pavletich,N. P. (1999). Crystal struc-
ture of the PTEN tumor suppressor:
implications for its phosphoinosi-
tide phosphatase activity and mem-
brane association. Cell 99, 323–334.
Lehman, N. L., Verschuren, E. W., Hsu,
J. Y., Cherry, A. M., and Jack-
son, P. K. (2006). Overexpression
of the anaphase promoting com-
plex/cyclosome inhibitor Emi1 leads
to tetraploidy and genomic instabil-
ity of p53-deﬁcient cells. Cell Cycle
5, 1569–1573.
Leverson, J. D., Joazeiro, C. A.,
Page, A. M., Huang, H., Hieter,
P., and Hunter, T. (2000). The
APC11 RING-H2 ﬁnger mediates
E2-dependent ubiquitination. Mol.
Biol. Cell 11, 2315–2325.
Li, D. M., and Sun, H. (1998).
PTEN/MMAC1/TEP1 suppresses
the tumorigenicity and induces G1
cell cycle arrest in human glioblas-
toma cells. Proc. Natl. Acad. Sci.
U.S.A. 95, 15406–15411.
Li, J., Yen, C., Liaw, D., Podsypanina,
K., Bose, S., Wang, S. I., Puc, J.,
Miliaresis, C., Rodgers, L., McCom-
bie, R., Bigner, S. H., Giovanella,
B. C., Ittmann, M., Tycko, B., Hib-
shoosh, H., Wigler, M. H., and Par-
sons, R. (1997). PTEN, a putative
protein tyrosine phosphatase gene
mutated in human brain, breast,
and prostate cancer. Science 275,
1943–1947.
Li, M., Shin, Y. H., Hou, L., Huang, X.,
Wei, Z., Klann, E., and Zhang, P.
(2008). The adaptor protein of the
anaphase promoting complex Cdh1
is essential inmaintaining replicative
lifespan and in learning and mem-
ory. Nat. Cell Biol. 10, 1083–1089.
Li, W., Wu, G., and Wan, Y. (2007).
The dual effects of Cdh1/APC
in myogenesis. FASEB J. 21,
3606–3617.
Li, X., Tang, X., Jablonska, B., Aguirre,
A., Gallo, V., and Luskin, M. B.
(2009). p27(KIP1) regulates neu-
rogenesis in the rostral migratory
stream and olfactory bulb of the
postnatal mouse. J. Neurosci. 29,
2902–2914.
Lim, M. S., Adamson, A., Lin, Z., Perez-
Ordonez, B., Jordan, R. C., Tripp,
S., Perkins, S. L., and Elenitoba-
Johnson, K. S. (2002). Expression of
Skp2, a p27(Kip1) ubiquitin ligase,
in malignant lymphoma: correlation
with p27(Kip1) and proliferation
index. Blood 100, 2950–2956.
Lin, H. K., Wang, G., Chen, Z., Teruya-
Feldstein, J., Liu, Y., Chan, C. H.,
Yang, W. L., Erdjument-Bromage,
H., Nakayama, K. I., Nimer, S.,
Tempst, P., and Pandolﬁ, P. P.
(2009). Phosphorylation-dependent
regulation of cytosolic localization
and oncogenic function of Skp2
by Akt/PKB. Nat. Cell Biol. 11,
420–432.
Lin, R., Wang, T. T., Miller, W. H.
Jr., and White, J. H. (2003). Inhi-
bition of F-box protein p45(SKP2)
expression and stabilization of
cyclin-dependent kinase inhibitor
p27(KIP1) in vitamin D analog-
treated cancer cells. Endocrinology
144, 749–753.
Lindon, C., and Pines, J. (2004).
Ordered proteolysis in anaphase
inactivates Plk1 to contribute to
proper mitotic exit in human cells.
J. Cell Biol. 164, 233–241.
Liot, C., Seguin, L., Siret, A., Crouin, C.,
Schmidt, S., and Bertoglio, J. (2011).
APC(cdh1) mediates degradation
of the oncogenic rho-GEF Ect2
after mitosis. PLoS ONE 6, e23676.
doi:10.1371/journal.pone.0023676
Lipkowitz, S., and Weissman, A. M.
(2011). RINGs of good and evil:
RING ﬁnger ubiquitin ligases at the
crossroads of tumour suppression
and oncogenesis. Nat. Rev. Cancer
11, 629–643.
Listovsky, T., Oren, Y. S., Yudkovsky,
Y., Mahbubani, H. M., Weiss, A.
M., Lebendiker, M., and Brandeis,
M. (2004). Mammalian Cdh1/Fzr
mediates its own degradation.
EMBO J. 23, 1619–1626.
Liu, H., Moy, P., Kim, S., Xia, Y.,
Rajasekaran, A., Navarro, V., Knud-
sen, B., and Bander, N. H. (1997).
Monoclonal antibodies to the extra-
cellular domain of prostate-speciﬁc
membrane antigen also react with
tumor vascular endothelium.Cancer
Res. 57, 3629–3634.
Liu, H. S., Ke, C. S., Cheng, H. C.,
Huang, C. Y., and Su, C. L. (2011a).
Curcumin-induced mitotic spindle
defect and cell cycle arrest in human
bladder cancer cells occurs partly
through inhibition of aurora A. Mol.
Pharmacol. 80, 638–646.
Liu, X. S., Song, B., Elzey, B. D., Ratliff,
T. L., Konieczny, S. F., Cheng, L.,
Ahmad, N., and Liu, X. (2011b).
Polo-like kinase 1 facilitates loss
of pten tumor suppressor-induced
prostate cancer formation. J. Biol.
Chem. 286, 35795–35800.
Liu, X., and Erikson, R. L. (2003). Polo-
like kinase (plk)1 depletion induces
apoptosis in cancer cells. Proc. Natl.
Acad. Sci. U.S.A. 100, 5789–5794.
Lopez-Bergami, P., Huang, C., Goydos,
J. S., Yip, D., Bar-Eli, M., Herlyn, M.,
Smalley, K. S., Mahale, A., Eroshkin,
A., Aaronson, S., and Ronai, Z.
(2007). Rewired ERK-JNK signaling
pathways in melanoma. Cancer Cell
11, 447–460.
Lu, M., Ma, J., Xue, W., Cheng, C.,
Wang, Y., Zhao, Y., Ke, Q., Liu,
H., Liu, Y., Li, P., Cui, X., He, S.,
and Shen, A. (2009). The expres-
sion and prognosis of FOXO3a
and Skp2 in human hepatocellular
carcinoma. Pathol. Oncol. Res. 15,
679–687.
Lukas, C., Sorensen, C. S., Kramer,
E., Santoni-Rugiu, E., Lin-
deneg, C., Peters, J. M., Bartek,
J., and Lukas, J. (1999). Accu-
mulation of cyclin B1 requires
E2F and cyclin-A-dependent
rearrangement of the anaphase-
promoting complex. Nature 401,
815–818.
Lukasiewicz, K. B., Greenwood, T. M.,
Negron, V. C., Bruzek, A. K., Sal-
isbury, J. L., and Lingle, W. L.
(2011). Control of centrin stability
by aurora A. PLoS ONE 6, e21291.
doi:10.1371/journal.pone.0021291
Luu, T. H., Morgan, R. J., Leong,
L., Lim, D., McNamara, M., Port-
now, J., Frankel, P., Smith, D. D.,
Doroshow, J. H.,Wong, C., Aparicio,
A., Gandara, D. R., and Somlo, G.
(2008). A phase II trial of vorinostat
Frontiers in Oncology | Molecular and Cellular Oncology January 2012 | Volume 1 | Article 60 | 16
Penas et al. APC/C role in cancer
(suberoylanilide hydroxamic acid)
inmetastatic breast cancer: aCalifor-
nia cancer consortium study. Clin.
Cancer Res. 14, 7138–7142.
Macmillan, J. C., Hudson, J. W., Bull,
S., Dennis, J. W., and Swallow, C.
J. (2001). Comparative expression
of the mitotic regulators SAK and
PLK in colorectal cancer. Ann. Surg.
Oncol. 8, 729–740.
Madoux, F., Simanski, S., Chase, P.,
Mishra, J. K., Roush, W. R., Ayad, N.
G., and Hodder, P. (2010). An ultra-
high throughput cell-based screen
for wee1 degradation inhibitors. J.
Biomol. Screen. 15, 907–917.
Maehama, T., and Dixon, J. E.
(1998). The tumor suppressor,
PTEN/MMAC1, dephosphorylates
the lipid second messenger,
phosphatidylinositol 3,4,5-
trisphosphate. J. Biol. Chem.
273, 13375–13378.
Maier, D., Jones, G., Li, X., Schonthal, A.
H., Gratzl, O., Van Meir, E. G., and
Merlo, A. (1999). The PTEN lipid
phosphatase domain is not required
to inhibit invasion of glioma cells.
Cancer Res. 59, 5479–5482.
Mamely, I., van Vugt, M. A., Smits, V.
A., Semple, J. I., Lemmens, B., Per-
rakis, A., Medema, R. H., and Freire,
R. (2006). Polo-like kinase-1 con-
trols proteasome-dependent degra-
dation of claspin during checkpoint
recovery. Curr. Biol. 16, 1950–1955.
Manchado, E., Guillamot, M., de
Carcer, G., Eguren, M., Trickey,
M., Garcia-Higuera, I., Moreno, S.,
Yamano, H., Canamero, M., and
Malumbres, M. (2010). Targeting
mitotic exit leads to tumor regres-
sion in vivo: modulation by Cdk1,
mastl, and the PP2A/B55alpha,delta
phosphatase. Cancer Cell 18,
641–654.
Margottin-Goguet, F., Hsu, J. Y., Lok-
tev, A., Hsieh, H. M., Reimann,
J. D., and Jackson, P. K. (2003).
Prophase destruction of Emi1 by the
SCF(betaTrCP/Slimb) ubiquitin lig-
ase activates the anaphase promot-
ing complex to allow progression
beyond prometaphase. Dev. Cell 4,
813–826.
Marino, S., Krimpenfort, P., Leung, C.,
van der Korput, H. A., Trapman, J.,
Camenisch, I., Berns, A., and Brand-
ner, S. (2002). PTEN is essential
for cell migration but not for fate
determination and tumourigenesis
in the cerebellum. Development 129,
3513–3522.
Marks, P., Rifkind, R. A., Richon, V. M.,
Breslow, R., Miller, T., and Kelly, W.
K. (2001). Histone deacetylases and
cancer: causes and therapies. Nat.
Rev. Cancer 1, 194–202.
Marx, M., Lebuhotel, C., Laugier, D.,
Chapelle, A., Calothy, G., and Saule,
S. (2010). Down regulation of pRb
in cultures of avian neuroretina cells
promotes proliferation of reactive
Muller-like cells and emergence of
retinal stem/progenitors. Exp. Eye
Res. 90, 791–801.
McCubrey, J. A., Steelman, L. S., Kempf,
C. R., Chappell, W. H., Abrams,
S. L., Stivala, F., Malaponte, G.,
Nicoletti, F., Libra, M., Bäsecke, J.,
Maksimovic-Ivanic, D., Mijatovic,
S.,Montalto,G.,Cervello,M.,Cocco,
L., and Martelli, A. M. (2011). Ther-
apeutic resistance resulting from
mutations in Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR signaling
pathways. J. Cell. Physiol. 226,
2762–2781.
McGarry, T. J., and Kirschner, M. W.
(1998). Geminin, an inhibitor of
DNA replication, is degraded during
mitosis. Cell 93, 1043–1053.
Meraldi, P., Lukas, J., Fry, A. M., Bartek,
J., and Nigg, E. A. (1999). Cen-
trosome duplication in mammalian
somatic cells requires E2F andCdk2-
cyclin A. Nat. Cell Biol. 1, 88–93.
Miller, J. J., Summers, M. K., Hansen,
D. V., Nachury, M. V., Lehman,
N. L., Loktev, A., and Jackson, P.
K. (2006). Emi1 stably binds and
inhibits the anaphase-promoting
complex/cyclosome as a pseudo-
substrate inhibitor. Genes Dev. 20,
2410–2420.
Miyoshi, Y., Iwao, K., Egawa, C., and
Noguchi, S. (2001). Association of
centrosomal kinase STK15/BTAK
mRNA expression with chromoso-
mal instability in human breast can-
cers. Int. J. Cancer 92, 370–373.
Modesitt, S. C., Sill, M., Hoffman, J.
S., Bender, D. P., and Gynecologic
Oncology Group. (2008). A phase II
study of vorinostat in the treatment
of persistent or recurrent epithelial
ovarian or primary peritoneal carci-
noma: a gynecologic oncology group
study. Gynecol. Oncol. 109, 182–186.
Mondal, G., Sengupta, S., Panda, C. K.,
Gollin, S. M., Saunders, W. S., and
Roychoudhury, S. (2007). Overex-
pression of Cdc20 leads to impair-
ment of the spindle assembly check-
point and aneuploidization in oral
cancer. Carcinogenesis 28, 81–92.
Montagnoli, A., Fiore, F., Eytan, E., Car-
rano, A. C., Draetta, G. F., Her-
shko, A., and Pagano, M. (1999).
Ubiquitination of p27 is regulated
by cdk-dependent phosphorylation
and trimeric complex formation.
Genes Dev. 13, 1181–1189.
Nakamura, Y., Ozaki, T., Koseki, H.,
Nakagawara, A., and Sakiyama, S.
(2003). Accumulation of p27 KIP1
is associated with BMP2-induced
growth arrest and neuronal differ-
entiation of human neuroblastoma-
derived cell lines. Biochem. Biophys.
Res. Commun. 307, 206–213.
Nakayama, J., Xiao, G., Noma, K.,
Malikzay, A., Bjerling, P., Ekwall,
K., Kobayashi, R., and Grewal, S. I.
(2003). Alp13, an MRG family pro-
tein, is a component of ﬁssion yeast
Clr6 histone deacetylase required
for genomic integrity. EMBO J. 22,
2776–2787.
Nguyen, L., Besson, A., Heng, J. I.,
Schuurmans, C., Teboul, L., Parras,
C., Philpott, A., Roberts, J. M., and
Guillemot, F. (2007). p27Kip1 inde-
pendently promotes neuronal differ-
entiation and migration in the cere-
bral cortex.Bull.Mem.Acad. R.Med.
Belg. 162, 310–314.
Nguyen, L., Besson, A., Roberts, J. M.,
and Guillemot, F. (2006). Coupling
cell cycle exit, neuronal differentia-
tion and migration in cortical neu-
rogenesis. Cell Cycle 5, 2314–2318.
Nilsson, J. (2011). Cdc20 control of
cell fate during prolonged mitotic
arrest: do Cdc20 protein levels affect
cell fate in response to antim-
itotic compounds? Bioessays 33,
903–909.
Nilsson, J., Yekezare, M., Minshull, J.,
and Pines, J. (2008). The APC/C
maintains the spindle assembly
checkpoint by targeting Cdc20 for
destruction. Nat. Cell Biol. 10,
1411–1420.
Noh, E. J., and Lee, J. S. (2003). Func-
tional interplay betweenmodulation
of histone deacetylase activity and
its regulatory role in G2-M transi-
tion. Biochem. Biophys. Res. Com-
mun. 310, 267–273.
North, B. J., Marshall, B. L., Borra,
M. T., Denu, J. M., and Verdin, E.
(2003). The human Sir2 ortholog,
SIRT2, is an NAD+-dependent
tubulin deacetylase. Mol. Cell 11,
437–444.
North,B. J., andVerdin, E. (2007). Inter-
phase nucleo-cytoplasmic shuttling
and localization of SIRT2 dur-
ing mitosis. PLoS ONE 2, e784.
doi:10.1371/journal.pone.0000784
Ohkura,H.,Hagan, I.M., andGlover,D.
M. (1995). The conserved schizosac-
charomyces pombe kinase plo1,
required to form a bipolar spindle,
the actin ring, and septum, can drive
septum formation in G1 and G2
cells. Genes Dev. 9, 1059–1073.
Okamoto, Y., Ozaki, T., Miyazaki, K.,
Aoyama, M., Miyazaki, M., and
Nakagawara, A. (2003). UbcH10
is the cancer-related E2 ubiquitin-
conjugating enzyme. Cancer Res. 63,
4167–4173.
Olsson, T. G., Silverstein, R. A.,
Ekwall, K., and Sunnerhagen, P.
(1999). Transient inhibition of his-
tone deacetylase activity overcomes
silencing in the mating-type region
in ﬁssion yeast. Curr. Genet. 35,
82–87.
Pallante, P., Berlingieri, M. T., Tron-
cone, G., Kruhoffer, M., Orntoft, T.
F., Viglietto, G., Caleo, A., Migliac-
cio, I., Decaussin-Petrucci, M., San-
toro, M., Palombini, L., and Fusco,
A. (2005). UbcH10 overexpression
may represent a marker of anaplastic
thyroid carcinomas. Br. J. Cancer 93,
464–471.
Pan, J., and Chen, R. H. (2004). Spindle
checkpoint regulates Cdc20p stabil-
ity in Saccharomyces cerevisiae.Genes
Dev. 18, 1439–1451.
Passmore, L. A., Booth, C. R., Venien-
Bryan, C., Ludtke, S. J., Fioretto, C.,
Johnson, L. N., Chiu, W., and Bar-
ford, D. (2005). Structural analy-
sis of the anaphase-promoting com-
plex reveals multiple active sites
and insights into polyubiquitylation.
Mol. Cell 20, 855–866.
Payne, D. M., Rossomando, A. J.,
Martino, P., Erickson, A. K., Her,
J. H., Shabanowitz, J., Hunt, D.
F., Weber, M. J., and Sturgill,
T. W. (1991). Identiﬁcation of
the regulatory phosphorylation sites
in pp42/mitogen-activated protein
kinase (MAP kinase). EMBO J. 10,
885–892.
Perk, J., Iavarone, A., and Benezra, R.
(2005). Id family of helix-loop-helix
proteins in cancer. Nat. Rev. Cancer
5, 603–614.
Perry, S. S., Zhao, Y., Nie, L., Cochrane,
S. W., Huang, Z., and Sun, X. H.
(2007). Id1, but not Id3, directs
long-term repopulating hematopoi-
etic stem-cell maintenance. Blood
110, 2351–2360.
Petersen, B. O., Wagener, C., Mari-
noni, F., Kramer, E. R., Melixet-
ian, M., Lazzerini Denchi, E., Gief-
fers, C., Matteucci, C., Peters, J. M.,
and Helin, K. (2000). Cell cycle-
and cell growth-regulated proteoly-
sis of mammalian CDC6 is depen-
dent on APC-CDH1. Genes Dev. 14,
2330–2343.
Pﬂeger, C. M., and Kirschner, M. W.
(2000). TheKENbox: anAPC recog-
nition signal distinct from the D box
targeted by Cdh1. Genes Dev. 14,
655–665.
Pihan, G. A., Purohit, A., Wallace, J.,
Malhotra, R., Liotta, L., and Doxsey,
S. J. (2001). Centrosome defects
can account for cellular and genetic
changes that characterize prostate
cancer progression. Cancer Res. 61,
2212–2219.
www.frontiersin.org January 2012 | Volume 1 | Article 60 | 17
Penas et al. APC/C role in cancer
Pines, J. (2011). Cubism and the cell
cycle: the many faces of the APC/C.
Nat. Rev. Mol. Cell Biol. 12, 427–438.
Podsypanina, K., Ellenson, L. H.,
Nemes, A., Gu, J., Tamura, M.,
Yamada, K. M., Cordon-Cardo, C.,
Catoretti, G., Fisher, P. E., and
Parsons, R. (1999). Mutation of
Pten/Mmac1 in mice causes neo-
plasia in multiple organ systems.
Proc. Natl. Acad. Sci. U.S.A. 96,
1563–1568.
Potapova, O., Gorospe, M., Bost, F.,
Dean, N. M., Gaarde, W. A., Mer-
cola, D., and Holbrook, N. J. (2000).
c-jun N-terminal kinase is essen-
tial for growth of human T98G
glioblastoma cells. J. Biol. Chem. 275,
24767–24775.
Pray, T. R., Parlati, F., Huang, J., Wong,
B. R., Payan, D. G., Bennett, M. K.,
Issakani, S. D., Molineaux, S., and
Demo, S. D. (2002). Cell cycle reg-
ulatory E3 ubiquitin ligases as anti-
cancer targets. Drug Resist. Updat. 5,
249–258.
Qian, Y. W., Erikson, E., Li, C., and
Maller, J. L. (1998). Activated polo-
like kinase Plx1 is required at
multiple points during mitosis in
Xenopus laevis. Mol. Cell. Biol. 18,
4262–4271.
Qiao, X., Zhang, L., Gamper, A. M.,
Fujita, T., and Wan, Y. (2010).
APC/C-Cdh1: from cell cycle to cel-
lular differentiation and genomic
integrity. Cell Cycle 9, 3904–3912.
Radke, S., Pirkmaier, A., and Germain,
D. (2005). Differential expression
of the F-box proteins Skp2 and
Skp2B in breast cancer.Oncogene 24,
3448–3458.
Rajasekaran, A. K., Anilkumar, G., and
Christiansen, J. J. (2005). Is prostate-
speciﬁc membrane antigen a mul-
tifunctional protein? Am. J. Physiol.
Cell Physiol. 288, C975–C981.
Rajasekaran, S. A., Christiansen, J. J.,
Schmid, I., Oshima, E., Ryazantsev,
S., Sakamoto, K., Weinstein, J., Rao,
N. P., and Rajasekaran, A. K. (2008).
Prostate-speciﬁc membrane antigen
associates with anaphase-promoting
complex and induces chromoso-
mal instability. Mol. Cancer Ther. 7,
2142–2151.
Rape, M., and Kirschner, M. W.
(2004). Autonomous regulation of
the anaphase-promoting complex
couples mitosis to S-phase entry.
Nature 432, 588–595.
Rape, M., Reddy, S. K., and Kirschner,
M. W. (2006). The processivity
of multiubiquitination by the APC
determines the order of substrate
degradation. Cell 124, 89–103.
Reed, S. I. (2008). Deathproof: new
insights on the role of skp2
in tumorigenesis. Cancer Cell 13,
88–89.
Reimann, J. D., Freed, E., Hsu, J. Y.,
Kramer, E. R., Peters, J. M., and Jack-
son, P. K. (2001). Emi1 is a mitotic
regulator that interacts with Cdc20
and inhibits the anaphase promoting
complex. Cell 105, 645–655.
Reynisdottir, I., Polyak, K., Iavarone, A.,
and Massague, J. (1995). Kip/Cip
and Ink4 cdk inhibitors cooperate to
induce cell cycle arrest in response to
TGF-beta. Genes Dev. 9, 1831–1845.
Rose, A. E., Wang, G., Hanniford,
D., Monni, S., Tu, T., Shapiro, R.
L., Berman, R. S., Pavlick, A. C.,
Pagano, M., Darvishian, F., Mazum-
dar, M., Hernando, E., and Osman,
I. (2011). Clinical relevance of SKP2
alterations in metastatic melanoma.
Pigment Cell Melanoma Res. 24,
197–206.
Ross, J. S., Sheehan, C. E., Fisher, H. A.,
Kaufman, R. P. Jr, Kaur, P., Gray, K.,
Webb, I., Gray, G. S., Mosher, R., and
Kallakury, B. V. (2003). Correlation
of primary tumor prostate-speciﬁc
membrane antigen expression with
disease recurrence inprostate cancer.
Clin. Cancer Res. 9, 6357–6362.
Ross, K. E., and Cohen-Fix, O. (2003).
The role of Cdh1p in maintaining
genomic stability in budding yeast.
Genetics 165, 489–503.
Rothschild, G., Zhao, X., Iavarone, A.,
and Lasorella, A. (2006). E proteins
and Id2 converge on p57Kip2 to reg-
ulate cell cycle in neural cells. Mol.
Cell. Biol. 26, 4351–4361.
Sabado Alvarez, C. (2008). Molecu-
lar biology of retinoblastoma. Clin.
Transl. Oncol. 10, 389–394.
Salhia, B., Tran, N. L., Chan, A., Wolf,
A., Nakada, M., Rutka, F., Ennis, M.,
McDonough, W. S., Berens, M. E.,
Symons, M., and Rutka, J. T. (2008).
The guanine nucleotide exchange
factors trio, Ect2, and Vav3 medi-
ate the invasive behavior of glioblas-
toma. Am. J. Pathol. 173, 1828–1838.
Sano, M., Genkai, N., Yajima, N.,
Tsuchiya, N., Homma, J., Tanaka, R.,
Miki, T., and Yamanaka, R. (2006).
Expression level of ECT2 proto-
oncogene correlates with prognosis
in glioma patients. Oncol. Rep. 16,
1093–1098.
Saunders, L. R., and Verdin, E. (2007).
Sirtuins: critical regulators at the
crossroads between cancer and
aging. Oncogene 26, 5489–5504.
Schöffski, P. (2009). Polo-like kinase
(PLK) inhibitors in preclinical and
early clinical development in oncol-
ogy. Oncologist 14, 559–570.
Schreiber, A., Stengel, F., Zhang, Z.,
Enchev, R. I., Kong, E. H., Morris, E.
P., Robinson, C. V., da Fonseca, P. C.,
and Barford, D. (2011). Structural
basis for the subunit assembly of
the anaphase-promoting complex.
Nature 470, 227–232.
Schuler, S., Diersch, S., Hamacher, R.,
Schmid, R. M., Saur, D., and Schnei-
der, G. (2011). SKP2 confers resis-
tance of pancreatic cancer cells
towards TRAIL-induced apoptosis.
Int. J. Oncol. 38, 219–225.
Schwickart, M., Havlis, J., Habermann,
B., Bogdanova, A., Camasses, A.,
Oelschlaegel, T., Shevchenko,A., and
Zachariae, W. (2004). Swm1/Apc13
is an evolutionarily conserved sub-
unit of the anaphase-promoting
complex stabilizing the association
of Cdc16 and Cdc27. Mol. Cell. Biol.
24, 3562–3576.
Seguin,L., Liot,C.,Mzali,R.,Harada,R.,
Siret, A., Nepveu, A., and Bertoglio,
J. (2009). CUX1 and E2F1 reg-
ulate coordinated expression of
the mitotic complex genes Ect2,
MgcRacGAP,andMKLP1 in Sphase.
Mol. Cell. Biol. 29, 570–581.
Sen, S., Zhou, H., Zhang, R. D., Yoon,
D. S., Vakar-Lopez, F., Ito, S., Jiang,
F., Johnston, D., Grossman, H. B.,
Ruifrok, A. C., Katz, R. L., Brink-
ley, W., and Czerniak, B. (2002).
Ampliﬁcation/overexpression of a
mitotic kinase gene in human blad-
der cancer. J. Natl. Cancer Inst. 94,
1320–1329.
Shomin, C. D., Restituyo, E., Cox, K.
J., and Ghosh, I. (2011). Selection
of cyclic-peptide inhibitors target-
ing aurora kinase A: problems and
solutions. Bioorg. Med. Chem. 19,
6743–6749.
Silva, A., Yunes, J. A., Cardoso, B. A.,
Martins, L. R., Jotta, P. Y., Abeca-
sis, M., Nowill, A. E., Leslie, N.
R., Cardoso, A. A., and Barata, J.
T. (2008). PTEN posttranslational
inactivation and hyperactivation of
the PI3K/Akt pathway sustain pri-
mary T cell leukemia viability. J.
Clin. Invest. 118, 3762–3774.
Silver, D. A., Pellicer, I., Fair, W. R.,
Heston, W. D., and Cordon-Cardo,
C. (1997). Prostate-speciﬁc mem-
brane antigen expression in normal
and malignant human tissues. Clin.
Cancer Res. 3, 81–85.
Silverstein, R. A., Richardson,W., Levin,
H., Allshire, R., and Ekwall, K.
(2003). A new role for the transcrip-
tional corepressor SIN3; regulation
of centromeres.Curr. Biol. 13,68–72.
Song, M. S., Carracedo, A., Salmena,
L., Song, S. J., Egia, A., Malum-
bres, M., and Pandolﬁ, P. P. (2011).
Nuclear PTEN regulates the APC-
CDH1 tumor-suppressive complex
in a phosphatase-independent man-
ner. Cell 144, 187–199.
Sorensen, C. S., Lukas, C., Kramer,
E. R., Peters, J. M., Bartek, J.,
and Lukas, J. (2000). Nonperiodic
activity of the human anaphase-
promoting complex-Cdh1 ubiq-
uitin ligase results in contin-
uous DNA synthesis uncoupled
from mitosis. Mol. Cell. Biol. 20,
7613–7623.
Steck, P. A., Pershouse, M. A., Jasser, S.
A., Yung, W. K., Lin, H., Ligon, A.
H., Langford, L. A., Baumgard, M.
L., Hattier, T., Davis, T., Frye, C., Hu,
R., Swedlund, B., Teng, D. H., and
Tavtigian, S. V. (1997). Identiﬁca-
tion of a candidate tumour suppres-
sor gene, MMAC1, at chromosome
10q23.3 that is mutated in multi-
ple advanced cancers.Nat. Genet. 15,
356–362.
Stegmuller, J., and Bonni, A. (2005).
Moving past proliferation: new roles
for Cdh1-APC in postmitotic neu-
rons. Trends Neurosci. 28, 596–601.
Strahl, B. D., and Allis, C. D. (2000).
The language of covalent his-
tone modiﬁcations. Nature 403,
41–45.
Strebhardt, K., Kneisel, L., Linhart, C.,
Bernd,A., and Kaufmann, R. (2000).
Prognostic value of polo like kinase
expression in melanomas. JAMA
283, 479–480.
Strebhardt, K., and Ullrich, A. (2006).
Targeting polo-like kinase 1 for can-
cer therapy. Nat. Rev. Cancer 6,
321–330.
Summers, M. K., Pan, B., Mukhyala,
K., and Jackson, P. K. (2008). The
unique N terminus of the UbcH10
E2 enzyme controls the threshold for
APC activation and enhances check-
point regulation of the APC. Mol.
Cell 31, 544–556.
Sweat, S. D., Pacelli, A., Murphy, G.
P., and Bostwick, D. G. (1998).
Prostate-speciﬁc membrane anti-
gen expression is greatest in
prostate adenocarcinoma and
lymph node metastases. Urology 52,
637–640.
Taddei, A., Roche, D., Sibarita, J. B.,
Huart, S., Maison, C., Bailly, D.,
and Almouzni, G. (2001). Localiz-
ing Replication Sites andNuclear Pro-
teins. Mapping Protein/DNA Interac-
tions by Cross-linking. Paris: Institut
national de la sante et de la recherche
medicale (INSERM).
Tamamori-Adachi, M., Hayashida, K.,
Nobori, K., Omizu, C., Yamada,
K., Sakamoto, N., Kamura, T.,
Fukuda, K., Ogawa, S., Nakayama,
K. I., and Kitajima, S. (2004).
Down-regulation of p27Kip1 pro-
motes cell proliferation of rat
neonatal cardiomyocytes induced by
nuclear expression of cyclin D1 and
Frontiers in Oncology | Molecular and Cellular Oncology January 2012 | Volume 1 | Article 60 | 18
Penas et al. APC/C role in cancer
CDK4. evidence for impaired Skp2-
dependent degradation of p27 in ter-
minal differentiation. J. Biol. Chem.
279, 50429–50436.
Tang, Z., Li, B., Bharadwaj, R., Zhu,
H., Ozkan, E., Hakala, K., Deisen-
hofer, J., and Yu, H. (2001). APC2
cullin protein andAPC11RINGpro-
tein comprise the minimal ubiqui-
tin ligase module of the anaphase-
promoting complex. Mol. Biol. Cell
12, 3839–3851.
Tarui, T., Takahashi, T., Nowakowski, R.
S., Hayes, N. L., Bhide, P. G., and
Caviness, V. S. (2005). Overexpres-
sion of p27 kip 1, probability of cell
cycle exit, and laminar destination of
neocortical neurons. Cereb. Cortex
15, 1343–1355.
Thoma, C. R., Toso, A., Meraldi, P.,
and Krek, W. (2011). Mechanisms
of aneuploidy and its suppression by
tumour suppressor proteins. Swiss.
Med. Wkly. 141, w13170.
Thornton, B. R., and Toczyski, D.
P. (2006). Precise destruction: an
emerging picture of the APC. Genes
Dev. 20, 3069–3078.
Tribukait, B. (1991). DNA ﬂow cytom-
etry in carcinoma of the prostate
for diagnosis, prognosis and study
of tumor biology. Acta Oncol. 30,
187–192.
Trosko, J. E. (2009). Review paper:
cancer stem cells and cancer non-
stem cells: from adult stem cells or
from reprogramming of differenti-
ated somatic cells. Vet. Pathol. 46,
176–193.
Troyer, J. K., Beckett, M. L., and Wright,
G. L. Jr. (1995). Detection and char-
acterization of the prostate-speciﬁc
membrane antigen (PSMA) in tis-
sue extracts and body ﬂuids. Int. J.
Cancer 62, 552–558.
Tsuiki, H., Tnani, M., Okamoto, I.,
Kenyon,L.C.,Emlet,D.R.,Holgado-
Madruga, M., Lanham, I. S., Joynes,
C. J.,Vo,K.T., andWong,A. J. (2003).
Constitutively active forms of c-jun
NH2-terminal kinase are expressed
in primary glial tumors. Cancer Res.
63, 250–255.
Tsvetkov, L.M.,Yeh,K.H., Lee, S. J., Sun,
H., and Zhang,H. (1999). p27(Kip1)
ubiquitination and degradation is
regulated by the SCF(Skp2) com-
plex through phosphorylated
Thr187 in p27. Curr. Biol. 9,
661–664.
Tury, A., Mairet-Coello, G., and
DiCicco-Bloom, E. (2011). The
cyclin-dependent kinase inhibitor
p57Kip2 regulates cell cycle exit,
differentiation, and migration
of embryonic cerebral cortical
precursors. Cereb. Cortex 21,
1840–1856.
Uddin, S., Hussain, A., Al-Hussein,
K., Platanias, L. C., and Bhatia,
K. G. (2004). Inhibition of phos-
phatidylinositol 3’-kinase induces
preferentially killing of PTEN-null
T leukemias through AKT path-
way. Biochem. Biophys. Res. Com-
mun. 320, 932–38.
van Ree, J. H., Jeganathan, K. B.,
Malureanu, L., and van Deursen, J.
M. (2010). Overexpression of the
E2 ubiquitin-conjugating enzyme
UbcH10 causes chromosome mis-
segregation and tumor formation. J.
Cell Biol. 188, 83–100.
Vaquero, A., Scher, M. B., Lee, D. H.,
Sutton, A., Cheng, H. L., Alt, F. W.,
Serrano, L., Sternglanz,R., and Rein-
berg, D. (2006). SirT2 is a histone
deacetylase with preference for his-
tone H4 lys 16 during mitosis. Genes
Dev. 20, 1256–1261.
Vernon, A. E., Devine, C., and Philpott,
A. (2003). The cdk inhibitor p27Xic1
is required for differentiation of pri-
mary neurones in Xenopus. Develop-
ment 130, 85–92.
Vidal, A., and Koff, A. (2000). Cell-cycle
inhibitors: three families united by a
common cause. Gene 247, 1–15.
Visintin, R., Prinz, S., and Amon, A.
(1997). CDC20 and CDH1: a fam-
ily of substrate-speciﬁc activators of
APC-dependent proteolysis. Science
278, 460–463.
Wai, D. H., Schaefer, K. L., Schramm,
A., Korsching, E., Van Valen, F.,
Ozaki, T., Boecker, W., Schweigerer,
L., Dockhorn-Dworniczak, B., and
Poremba, C. (2002). Expression
analysis of pediatric solid tumor
cell lines using oligonucleotide
microarrays. Int. J. Oncol. 20,
441–451.
Walker, S. M., Leslie, N. R., Perera, N.
M., Batty, I. H., and Downes, C.
P. (2004). The tumour-suppressor
function of PTEN requires an
N-terminal lipid-binding motif.
Biochem. J. 379, 301–307.
Wang,L.Y., andKung,H. J. (2011).Male
germ cell-associated kinase is over-
expressed inprostate cancer cells and
causes mitotic defects via deregula-
tion of APC/C(CDH1). Oncogene.
doi: 10.1038/onc.2011.464. [Epub
ahead of print].
Wang, Q., Moyret-Lalle, C., Couzon, F.,
Surbiguet-Clippe, C., Saurin, J. C.,
Lorca, T., Navarro, C., and Puisieux,
A. (2003). Alterations of anaphase-
promoting complex genes in human
colon cancer cells. Oncogene 22,
1486–1490.
Wang, R. H., Sengupta, K., Li, C., Kim,
H. S., Cao, L., Xiao, C., Kim, S., Xu,
X., Zheng, Y., Chilton, B., Jia, R.,
Zheng, Z. M., Appella, E., Wang, X.
W.,Ried,T., andDeng,C. X. (2008a).
Impaired DNA damage response,
genome instability, and tumorigen-
esis in SIRT1 mutant mice. Cancer
Cell 14, 312–323.
Wang, R. H., Zheng, Y., Kim, H. S.,
Xu, X., Cao, L., Luhasen, T., Lee,
M. H., Xiao, C., Vassilopoulos, A.,
Chen, W., Gardner, K., Man, Y.
G., Hung, M. C., Finkel, T., and
Deng, C. X. (2008b). Interplay
among BRCA1, SIRT1, and sur-
vivin during BRCA1-associated
tumorigenesis. Mol. Cell 32,
11–20.
Wang, X., and Dai, W. (2005).
Shugoshin, a guardian for sister
chromatid segregation. Exp. Cell Res.
310, 1–9.
Wasch, R., and Engelbert, D. (2005).
Anaphase-promoting complex-
dependent proteolysis of cell cycle
regulators and genomic instabil-
ity of cancer cells. Oncogene 24,
1–10.
Watanabe, N., Arai, H., Nishihara,
Y., Taniguchi, M., Watanabe,
N., Hunter, T., and Osada, H.
(2004). M-phase kinases induce
phospho-dependent ubiquitination
of somatic Wee1 by SCFbeta-TrCP.
Proc. Natl. Acad. Sci. U.S.A. 101,
4419–4424.
Wei, W., Ayad, N. G., Wan, Y., Zhang,
G. J., Kirschner, M. W., and Kaelin,
W. G. Jr. (2004). Degradation of
the SCF component Skp2 in cell-
cycle phase G1 by the anaphase-
promoting complex. Nature 428,
194–198.
Weichert, W., Schmidt, M., Gekeler,
V., Denkert, C., Stephan, C., Jung,
K., Loening, S., Dietel, M., and
Kristiansen, G. (2004). Polo-like
kinase 1 is overexpressed in prostate
cancer and linked to higher tumor
grades. Prostate 60, 240–245.
Westermann, F., Henrich, K. O.,
Wei, J. S., Lutz, W., Fischer, M.,
Konig, R., Wiedemeyer, R., Ehe-
mann, V., Brors, B., Ernestus, K.,
Leuschner, I., Benner, A., Khan, J.,
and Schwab, M. (2007). High Skp2
expression characterizes high-risk
neuroblastomas independent of
MYCN status. Clin. Cancer Res. 13,
4695–4703.
Wickliffe, K. E., Lorenz, S., Wemmer,
D. E., Kuriyan, J., and Rape, M.
(2011a). The mechanism of linkage-
speciﬁc ubiquitin chain elongation
by a single-subunit E2. Cell 144,
769–781.
Wickliffe, K. E., Williamson, A., Meyer,
H. J.,Kelly,A., andRape,M. (2011b).
K11-linked ubiquitin chains as novel
regulators of cell division. Trends
Cell Biol. 21, 656–663.
Williamson, A., Wickliffe, K. E., Mel-
lone, B. G., Song, L., Karpen, G. H.,
and Rape, M. (2009). Identiﬁcation
of a physiological E2 module for the
human anaphase-promoting com-
plex.Proc.Natl.Acad. Sci.U.S.A. 106,
18213–18218.
Wirth, K. G., Ricci, R., Gimenez-Abian,
J. F., Taghybeeglu, S., Kudo, N. R.,
Jochum, W., Vasseur-Cognet, M.,
and Nasmyth, K. (2004). Loss of
the anaphase-promoting complex in
quiescent cells causes unscheduled
hepatocyte proliferation. Genes Dev.
18, 88–98.
Wohlschlegel, J. A., Dwyer, B. T., Dhar,
S. K., Cvetic, C., Walter, J. C.,
and Dutta, A. (2000). Inhibition of
eukaryotic DNA replication by gem-
inin binding to Cdt1. Science 290,
2309–2312.
Wolf,G., Elez, R.,Doermer,A.,Holtrich,
U., Ackermann, H., Stutte, H. J.,
Altmannsberger, H. M., Rübsamen-
Waigmann, H., and Strebhardt, K.
(1997). Prognostic signiﬁcance of
polo-like kinase (PLK) expression in
non-small cell lung cancer.Oncogene
14, 543–549.
Wolf, G., Hildenbrand, R., Schwar, C.,
Grobholz, R., Kaufmann, M., Stutte,
H. J., Strebhardt, K., and Bleyl, U.
(2000). Polo-like kinase: a novel
marker of proliferation: correlation
with estrogen-receptor expression in
human breast cancer. Pathol. Res.
Pract. 196, 753–759.
Wu, G., Glickstein, S., Liu, W., Fujita,
T., Li, W., Yang, Q., Duvoisin,
R., and Wan, Y. (2007). The
anaphase-promoting complex coor-
dinates initiation of lens dif-
ferentiation. Mol. Biol. Cell 18,
1018–1029.
Wu, G., Qiu, X. L., Zhou, L.,
Zhu, J., Chamberlin, R., Lau, J.,
Chen, P. L., and Lee, W. H.
(2008). Small molecule targeting the
Hec1/Nek2 mitotic pathway sup-
presses tumor cell growth in cul-
ture and in animal. Cancer Res. 68,
8393–8399.
Wu, T., Merbl, Y., Huo, Y., Gallop,
J. L., Tzur, A., and Kirschner, M.
W. (2010). UBE2S drives elongation
of K11-linked ubiquitin chains by
the anaphase-promoting complex.
Proc. Natl. Acad. Sci. U.S.A. 107,
1355–1360.
Xia, H. H., He, H., De Wang, J., Gu,
Q., Lin, M. C., Zou, B., Yu, L. F.,
Sun, Y. W., Chan, A. O., Kung, H.
F., and Wong, B. C. (2006). Induc-
tion of apoptosis and cell cycle arrest
by a speciﬁc c-jun NH2-terminal
kinase (JNK) inhibitor, SP-600125,
in gastrointestinal cancers. Cancer
Lett. 241, 268–274.
www.frontiersin.org January 2012 | Volume 1 | Article 60 | 19
Penas et al. APC/C role in cancer
Xia, L., Robinson, D., Ma, A. H.,
Chen, H. C., Wu, F., Qiu, Y., and
Kung, H. J. (2002). Identiﬁcation
of human male germ cell-associated
kinase, a kinase transcriptionally
activated by androgen in prostate
cancer cells. J. Biol. Chem. 277,
35422–35433.
Xu, W. J., Zhang, S., Yang, Y., Zhang, N.,
Wang,W., Liu, S. Y., Tian,H.W.,Dai,
L., Xie, Q., Zhao, X., Wei, Y. Q., and
Deng, H. X. (2011). Efﬁcient inhibi-
tion of human colorectal carcinoma
growth by RNA interference target-
ing polo-like kinase 1 in vitro and
in vivo. Cancer Biother. Radiopharm.
26, 427–436.
Yang, G., Ayala, G., De Marzo, A.,
Tian, W., Frolov, A., Wheeler, T.
M., Thompson, T. C., and Harper,
J. W. (2002). Elevated Skp2 pro-
tein expression in human prostate
cancer: association with loss of the
cyclin-dependent kinase inhibitor
p27 and PTEN and with reduced
recurrence-free survival. Clin. Can-
cer Res. 8, 3419–3426.
Yang, Y. M., Bost, F., Charbono, W.,
Dean, N., McKay, R., Rhim, J. S.,
Depatie, C., and Mercola, D. (2003).
C-jun NH(2)-terminal kinase medi-
ates proliferation and tumor growth
of human prostate carcinoma. Clin.
Cancer Res. 9, 391–401.
Yao, W., Qian, W., Zhu, C., Gui, L., Qiu,
J., and Zhang, C. (2010). Cdh1-APC
is involved in the differentiation of
neural stem cells into neurons. Neu-
roreport 21, 39–44.
Ye, Y., and Rape, M. (2009). Build-
ing ubiquitin chains: E2 enzymes at
work. Nat. Rev. Mol. Cell Biol. 10,
755–764.
Yokoi, S., Yasui, K., Iizasa, T., Taka-
hashi, T., Fujisawa, T., and Inazawa,
J. (2003). Down-regulation of SKP2
induces apoptosis in lung-cancer
cells. Cancer Sci. 94, 344–349.
Yokota, Y. (2001). Id and development.
Oncogene 20, 8290–8298.
Yoon, H. E., Kim, S. A., Choi, H.
S., Ahn, M. Y., Yoon, J. H.,
and Ahn, S. G. (2011). Inhibi-
tion of Plk1 and Pin1 by 5′-nitro-
indirubinoxime suppresses human
lung cancer cells. Cancer Lett. doi:
10.1016/j.canlet.2011.10.029. [Epub
ahead of print].
Yoshida, M., Shimazu, T., and Mat-
suyama, A. (2003). Protein deacety-
lases: enzymeswith functional diver-
sity as novel therapeutic targets.
Prog. Cell Cycle Res. 5, 269–278.
Yu, Z. K., Gervais, J. L., and Zhang,
H. (1998). Human CUL-1 asso-
ciates with the SKP1/SKP2 complex
and regulates p21(CIP1/WAF1) and
cyclin D proteins. Proc. Natl. Acad.
Sci. U.S.A. 95, 11324–11329.
Yuan, B., Xu, Y., Woo, J. H., Wang, Y.,
Bae, Y. K., Yoon, D. S., Wersto, R. P.,
Tully, E., Wilsbach, K., and Gabriel-
son, E. (2006). Increased expres-
sion of mitotic checkpoint genes in
breast cancer cells with chromoso-
mal instability. Clin. Cancer Res. 12,
405–410.
Zachariae, W., and Nasmyth, K. (1999).
Whose end is destruction: cell divi-
sion and the anaphase-promoting
complex. Genes Dev. 13, 2039–2058.
Zeng, X., Sigoillot, F., Gaur, S., Choi,
S., Pfaff, K. L., Oh, D. C., Hath-
away, N., Dimova, N., Cuny, G. D.,
and King, R. W. (2010). Pharma-
cologic inhibition of the anaphase-
promoting complex induces a spin-
dle checkpoint-dependent mitotic
arrest in the absence of spindle dam-
age. Cancer Cell 18, 382–395.
Zhang, L., Park, C. H., Wu, J., Kim,
H., Liu, W., Fujita, T., Balasubra-
mani, M., Schreiber, E. M., Wang,
X. F., and Wan, Y. (2010). Proteoly-
sis of Rad17 by Cdh1/APC regulates
checkpoint termination and recov-
ery from genotoxic stress. EMBO J.
29, 1726–1737.
Zhang, P., Wong, C., Liu, D., Finegold,
M., Harper, J. W., and Elledge, S. J.
(1999). p21(CIP1) and p57(KIP2)
control muscle differentiation at
the myogenin step. Genes Dev. 13,
213–224.
Zheng, L., Chen, Y., and Lee, W.
H. (1999). Hec1p, an evolution-
arily conserved coiled-coil pro-
tein, modulates chromosome seg-
regation through interaction with
SMC proteins. Mol. Cell. Biol. 19,
5417–5428.
Zheng, N., Schulman, B. A., Song, L.,
Miller, J. J., Jeffrey, P. D., Wang,
P., Chu, C., Koepp, D. M., Elledge,
S. J., Pagano, M., Conaway, R. C.,
Conaway, J. W., Harper, J. W., and
Pavletich, N. P. (2002). Structure of
theCul1-Rbx1-Skp1-F boxSkp2 SCF
ubiquitin ligase complex. Nature
416, 703–709.
Zhou, H., Kuang, J., Zhong, L.,
Kuo, W. L., Gray, J. W., Sahin,
A., Brinkley, B. R., and Sen, S.
(1998). Tumour ampliﬁed kinase
STK15/BTAK induces centrosome
ampliﬁcation, aneuploidy and
transformation. Nat. Genet. 20,
189–193.
Zhu, L., and Skoultchi, A. I. (2001).
Coordinating cell proliferation and
differentiation. Curr. Opin. Genet.
Dev. 11, 91–97.
Zhu, Q., Pearson-White, S., and Luo,
K. (2005). Requirement for the
SnoN oncoprotein in transforming
growth factor beta-induced onco-
genic transformation of ﬁbrob-
last cells. Mol. Cell. Biol. 25,
10731–10744.
Zhu, W., and Depamphilis, M. L.
(2009). Selective killing of cancer
cells by suppression of gem-
inin activity. Cancer Res. 69,
4870–4877.
Zibat, A., Missiaglia, E., Rosenberger,
A., Pritchard-Jones, K., Shipley, J.,
Hahn,H., and Fulda, S. (2010). Acti-
vation of the hedgehogpathway con-
fers a poor prognosis in embry-
onal and fusion gene-negative alve-
olar rhabdomyosarcoma. Oncogene
29, 6323–6330.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 30 November 2011; paper
pending published: 15 December 2011;
accepted: 22 December 2011; published
online: 09 January 2012.
Citation: Penas C, Ramachandran V
and Ayad NG (2012) The APC/C
ubiquitin ligase: from cell biology to
tumorigenesis. Front. Oncol. 1:60. doi:
10.3389/fonc.2011.00060
This article was submitted to Frontiers
in Molecular and Cellular Oncology, a
specialty of Frontiers in Oncology.
Copyright © 2012 Penas, Ramachan-
dran and Ayad. This is an open-access
article distributed under the terms of
the Creative Commons Attribution Non
Commercial License, which permits non-
commercial use, distribution, and repro-
duction in other forums, provided the
original authors and source are credited.
Frontiers in Oncology | Molecular and Cellular Oncology January 2012 | Volume 1 | Article 60 | 20
